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Glossary 
The majority of the following definitions are from the WHO publication on 
malaria terminology, which is subject to periodic update. For the latest
edition, please see: www.who.int/malaria/publications/atoz/malaria-
terminology/en/. Definitions not yet captured in the WHO malaria 
terminology document are indicated with an asterisk.
anthropophilic Description of mosquitoes that show a preference for 
feeding on humans, even when non-human hosts are 
available. 
Note: A relative term requiring quantification to indicate 
the extent of the mosquitoes’ preference for anthropophily 
versus zoophily, usually expressed as the human blood 
index (proportion of mosquitoes that have fed on humans 
out of total that have fed).
artemisinin-based 
combination 
therapy
The combination of an artemisinin derivative with a 
longer acting antimalarial drug that has a different 
mode of action.
bioassay In applied entomology, experimental testing of the 
biological effectiveness of a treatment (e.g. infection, 
insecticide, pathogen, predator, repellent) by 
deliberately exposing insects to the treatment 
Note: When bioassays are used for the periodic 
monitoring of the continued efficacy of residual 
insecticide deposits on sprayed surfaces in houses (as 
in indoor residual spraying), attention should be paid 
to the environmental conditions and possible adverse 
factors (e.g. washing, re-plastering, soot) that affect the 
deposits on treated surfaces; these factors may reduce 
the effectiveness of treatment in a way that differs from 
the intrinsic rate of decay of the insecticide.
biological 
insecticide*
Pesticides made from natural materials that are meant 
to kill or control insects. These natural source materials 
may include animals, plants, bacteria or minerals.
biting rate Average number of mosquito bites received by a 
host in a unit of time, specified according to host and 
mosquito species (usually measured by human landing 
collection). 
Note: Human malariology mainly requires the ‘human 
biting rate’ of vectors.
vi
coverage, 
universal
Access to and use of appropriate interventions by the 
entire population at risk of malaria.
endemic area An area in which there is an ongoing, measurable 
incidence of malaria infection and mosquito-borne 
transmission over a succession of years.
endemicity,
level of
Degree of malaria transmission in an area. 
Note: Various terms have been used to designate levels of 
endemicity, but none is fully satisfactory. Parasite rate or 
spleen rate has been used to define levels of endemicity 
in children aged 2–9 years, i.e. hypoendemic: 0–10%, 
mesoendemic: 10–50%, hyperendemic: constantly > 50% 
and holoendemic: constantly ≥ 75% with a low adult 
spleen rate. Parasite density decreases rapidly between 
2 and 5 years of age.
endophagy Tendency of mosquitoes to blood-feed indoors. 
Note: Contrasts with exophagy.
endophily Tendency of mosquitoes to rest indoors; usually 
quantified as the proportion of mosquitoes resting 
indoors; used in assessing the effect of indoor residual 
spraying
Note: Contrasts with exophily. 
entomological 
inoculation rate
Number of infective bites received per person in a 
given unit of time in a human population. 
Note: This rate is the product of the ‘human biting rate’ 
(the number of bites per person per day by vector 
mosquitoes) and the sporozoite rate (proportion of 
vector mosquitoes that are infective). At low levels of 
transmission, the estimated entomological inoculation 
rate may not be reliable, and alternative methods should 
be considered for evaluating transmission risk.
exophagy Tendency of mosquitoes to blood feed outdoors. 
Note: Contrasts with endophagy; usually quantified as 
the proportion biting hosts outdoors versus indoors, 
conveniently assessed by comparative human landing 
catches outdoors and indoors or by observation of biting 
rates on non-human hosts outdoors.
exophily Tendency of mosquitoes to rest outdoors; usually 
quantified as the proportion of mosquitoes resting 
outdoors versus indoors; used in estimating outdoor 
transmission risks.
Note: Contrasts with endophily.
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indoor residual 
spraying
Operational procedure and strategy for malaria 
vector control that involves spraying interior surfaces 
of dwellings with a residual insecticide to kill or repel 
endophilic mosquitoes.
infectious Capable of transmitting infection; a term commonly 
applied to human hosts.
infective Capable of producing infection; a term commonly 
applied to parasites (e.g. gametocytes, sporozoites) or 
to the vector (mosquito).
infectivity* Ability of a Plasmodium strain to establish an infection 
in an anopheline mosquito species and undergo 
development until the mosquito has sporozoites in its 
salivary glands.
insecticide Chemical product (natural or synthetic) that kills 
insects: Ovicides kill eggs; larvicides (larvacides) kill 
larvae; pupacides kill pupae; adulticides kill adult 
mosquitoes. Residual insecticides remain active for an 
extended period. 
Note: WHO maintains a prequalification listing of vector 
control products (1). 
insecticide 
resistance
Property of mosquitoes to survive exposure to a 
standard dose of insecticide; may be the result of 
physiological or behavioural adaptation. 
Note: The emergence of insecticide resistance in a 
vector population is an evolutionary phenomenon due 
to either behavioural avoidance (e.g. exophily instead of 
endophily) or physiological factors whereby the insecticide 
is metabolized, not potentiated, or absorbed less than by 
susceptible mosquitoes.
integrated vector 
management
Rational decision-making for optimal use of resources 
for vector control 
Note: The aim is to improve the efficacy, cost-
effectiveness, ecological soundness and sustainability of 
vector control activities against vector-borne diseases.
viii
larval source 
management
Management of aquatic habitats (water bodies) that 
are potential habitats for mosquito larvae in order to 
prevent completion of development of the immature 
stages.
Note: The four types of larval source management are: 
i) habitat modification, which is a permanent alteration 
of the environment, e.g. land reclamation; ii) habitat 
manipulation, which is a recurrent activity, e.g. flushing of 
streams; iii) larviciding, which is the regular application of 
biological or chemical insecticides to water bodies; and 
iv) biological control, which consists of the introduction of 
natural predators into water bodies.
larvicide Substance used to kill mosquito larvae. 
Note: Larvicides are applied in the form of oils (to 
asphyxiate larvae and pupae), emulsions, or small pellets 
or granules of inert carrier impregnated with insecticide, 
which is released gradually when they are placed in 
water.
malaria control Reduction of disease incidence, prevalence, morbidity 
or mortality to a locally acceptable level as a result of 
deliberate efforts. Continued interventions are required 
to sustain control.
malaria 
elimination
Interruption of local transmission (reduction to zero 
incidence of indigenous cases) of a specified malaria 
parasite in a defined geographical area as a result of 
deliberate activities. Continued measures to prevent 
re-establishment of transmission are required. 
Note: The certification of malaria elimination in a country 
requires local transmission to be interrupted for all human 
malaria parasites.
malaria 
eradication
Permanent reduction to zero of the worldwide 
incidence of infection caused by human malaria 
parasites as a result of deliberate activities. 
Interventions are no longer required once eradication 
has been achieved.
malaria 
prevalence 
(parasite 
prevalence)
Proportion of a specified population with malaria 
infection at one time.
malaria incidence Number of newly diagnosed malaria cases during a 
defined period in a specified population.
malariogenic 
potential*
The risk of malaria transmission; the product of 
receptivity, vulnerability and mosquito infectivity.
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malarious area Area in which transmission of malaria is occurring or 
has occurred during the preceding three years.
net, insecticide-
treated*
Mosquito net that repels, disables or kills mosquitoes 
that come into contact with the insecticide on the 
netting material. The three categories of insecticide-
treated net are:
• Conventionally treated net: a mosquito net that 
has been treated by dipping it into a WHO-
recommended insecticide. To ensure its continued 
insecticidal effect, the net should be re-treated 
periodically.
• Long-lasting insecticidal net: a factory-treated 
mosquito net made of netting material with 
insecticide incorporated within or bound around the 
fibres. The net must retain its effective biological 
activity for at least 20 WHO standard washes 
under laboratory conditions and three years of 
recommended use under field conditions.
• Pyrethroid-PBO net: a mosquito net that includes 
both a pyrethroid insecticide and the synergist 
piperonyl butoxide. To date, pyrethroid-PBO nets 
have not met required thresholds to qualify as long-
lasting insecticidal nets.
Note: Untreated mosquito nets can also provide 
substantial protection against mosquito bites, but 
they have less effect against vectorial capacity and 
transmission rates.
plasmodium Genus of protozoan blood parasites of vertebrates that 
includes the causal agents of malaria. P. falciparum, 
P. malariae, P. ovale and P. vivax cause malaria in 
humans. Human infection with the monkey malaria 
parasite P. knowlesi and very occasionally with other 
simian malaria species may occur in tropical forest 
areas.
prequalification Process to ensure that health products are safe, 
appropriate and meet stringent quality standards for 
international procurement. 
Note: Health products are prequalified through 
an assessment of product dossiers, inspection of 
manufacturing and testing sites, quality control testing 
in the case of vaccines and medicines, validation of the 
performance of diagnostic tests and verification that the 
products are suitable for use in the destination countries.
xPublic health 
intervention*
A public health intervention is any effort or policy that 
attempts to improve mental and physical health on 
a population level. Common types of interventions 
include screening programmes, vaccination, food 
and water supplementation, and health promotion. 
Common issues that are the subject of public health 
interventions include obesity, drug, tobacco and 
alcohol use, and the spread of infectious diseases such 
as malaria.
An effort or policy may meet the criteria of a public 
heath intervention if it prevents disease on both the 
individual and community level and has a positive 
impact on public health. For malaria vector control 
tools, technologies and approaches designed to 
prevent disease at the community level (e.g. IRS and 
ITNs), demonstration of public health value is required 
for WHO to issue a policy recommendation.
public health 
value*
A product has public health value if it has proven 
protective efficacy to reduce or prevent infection and/
or disease in humans.
Note: Public health value = epidemiological impact
receptivity Receptivity of an ecosystem to transmission of malaria.
Note: A receptive ecosystem should have e.g. the 
presence of competent vectors, a suitable climate and a 
susceptible population.
repellent Any substance that causes avoidance in mosquitoes, 
especially substances that deter them from settling on 
the skin of the host (topical repellent) or entering an 
area or room (area repellent, spatial repellent, excito-
repellent).
sporozoite Motile stage of the malaria parasite that is inoculated 
by a feeding female anopheline mosquito and may 
cause infection.
surveillance Continuous, systematic collection, analysis and 
interpretation of disease-specific data for use in 
planning, implementing and evaluating public health 
practice. 
Note: Surveillance can be done at different levels of the 
health care system (e.g. health facilities, the community), 
with different detection systems (e.g. case-based: active 
or passive) and sampling strategies (e.g. sentinel sites, 
surveys).
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synergist* A substance that does not itself have insecticidal 
properties, but that, when mixed and applied with 
insecticides of a particular class, considerably 
enhances their potency by inhibiting an enzyme that 
normally acts to detoxify the insecticide in the insect 
system.
transmission 
intensity
The frequency with which people living in an area 
are bitten by anopheline mosquitoes carrying human 
malaria sporozoites. 
Note: Transmission intensity is often expressed as the 
annual entomological inoculation rate, which is the 
average number of inoculations with malaria parasites 
estimated to be received by one person in a given period. 
Because of the difficulty of measuring entomological 
inoculation rate, parasite prevalence in young children is 
often used as a proxy for transmission intensity.
transmission, 
residual
Persistence of malaria transmission following the 
implementation in time and space of a widely effective 
malaria programme.
Note: The sources of and risks for ‘residual transmission’ 
may vary by location, time and the existing components of 
the current ‘effective malaria programme’.
transmission, 
seasonal
Transmission that occurs only during some months of 
the year and is markedly reduced during other months.
transmission, 
stable
Epidemiological type of malaria transmission 
characterized by a steady prevalence pattern, with 
little variation from one year to the next, except as 
the result of rapid scaling up of malaria interventions 
or exceptional environmental changes that affect 
transmission. 
Note: In areas with stable transmission, the affected 
population often has high levels of immunity, and malaria 
vectors usually have high longevity and human biting 
rates.
transmission, 
unstable
Epidemiological type of malaria transmission 
characterized by large variation in incidence patterns 
from one year to the next. 
Note: In areas with unstable transmission, epidemics are 
common and the population usually has little immunity.
xii
vector In malaria, adult females of any mosquito species 
in which Plasmodium undergoes its sexual cycle 
(whereby the mosquito is the definitive host of the 
parasite) to the infective sporozoite stage (completion 
of extrinsic development), ready for transmission when 
a vertebrate host is bitten. 
Note: Malaria vector species are usually implicated 
(incriminated) after field collection and dissection 
indicates that the salivary glands are infected with 
sporozoites; specific assays can be used to detect and 
identify circumsporozoite protein, especially where 
infection rates are low.
• Principal vector: The species of Anopheles mainly 
responsible for transmitting malaria in any 
particular circumstance. 
Note: Principal vectors may overlap seasonally or 
alternate in importance.
• Secondary or subsidiary vector: Species of 
Anopheles thought to play a lesser role in 
transmission than the principal vector; capable of 
maintaining malaria transmission at a reduced level. 
vector control Measures of any kind against malaria-transmitting 
mosquitoes, intended to limit their ability to transmit 
the disease. 
Note: Ideally, malaria vector control results in the 
reduction of malaria transmission rates by reducing the 
vectorial capacity to a point at which transmission is 
interrupted.
Note: vector control interventions include tools, 
technologies and approaches.
vector 
susceptibility
The degree to which a mosquito population is 
susceptible (i.e. not resistant) to insecticides.
vectorial capacity Number of new infections that the population of a 
given vector would induce per case per day at a given 
place and time, assuming that the human population 
is and remains fully susceptible to malaria.
vulnerability The frequency of influx of infected individuals or 
groups and/or infective anopheline mosquitoes.
Note: Also referred to as ‘importation risk’. The term can 
also be applied to the introduction of drug resistance in a 
specific area.
Source: WHO malaria terminology (2) except where indicated by an asterisk (*)
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Abbreviations
ANC antenatal care
CIDG Cochrane Infectious Diseases Group
EIR entomological inoculation rate
EPI expanded programme on immunization
GMP Global Malaria Programme
GRADE grading of recommendations assessment, 
development and evaluation
IRM insecticide resistance management
IRS indoor residual spraying
ISO International Organization for Standardization
ITN insecticide-treated net
ITPS insecticide-treated plastic sheeting
IVM integrated vector management
LLIN long-lasting insecticidal net
LSM larval source management
MPAC Malaria Policy Advisory Committee
PBO piperonyl butoxide
PICO population, participants or patients; intervention or 
indicator; comparator or control; outcome
PQ prequalification (WHO)
RCT randomized controlled trial
VCAG Vector Control Advisory Group
VCTEG Technical Expert Group on Malaria Vector Control
WHO World Health Organization
xiv
Executive summary
Vector control is a vital component of malaria prevention, control and 
elimination strategies because it can be highly effective in providing 
personal protection and/or reducing disease transmission. This 1st edition of 
the World Health Organization (WHO) Guidelines for malaria vector control 
has been prepared in accordance with the latest WHO standard methods 
for guideline development. It is a consolidated document that incorporates: 
i) new recommendations based on systematic reviews of the available 
evidence on the effectiveness of most, but not yet all, vector control 
interventions; and ii) existing recommendations developed previously 
based on expert opinion. Reviews on other interventions are ongoing, and 
the findings will be added to later editions of the Guidelines. The primary 
aim of consolidating the available evidence and recommendations was 
to condense the large, yet fragmented volume of available guidance into 
an up-to-date and coherent resource for national malaria programmes 
and their implementing partners. In cases where readers observe 
inconsistencies with earlier WHO publications, the Guidelines should be 
considered to supersede prior guidance. 
The Guidelines cover core interventions, supplementary interventions, 
personal protection measures and other interventions. Core interventions 
for malaria vector control are applicable for all populations at risk of 
malaria in most epidemiological and ecological settings, namely:  
i) deployment of insecticide-treated nets (ITNs) that are prequalified by 
WHO, which in many settings are long-lasting insecticidal nets (LLINs); 
and ii) indoor residual spraying (IRS) with a product prequalified by 
WHO. Once high coverage with one core intervention has been achieved, 
supplementary interventions – namely the deployment of chemical or 
biological larvicides – can be used in addition to the core interventions in 
specific settings and circumstances. 
The evidence base for larval source management through habitat 
modification and habitat manipulation was not considered in the 
preparation of this edition of the Guidelines, but will be covered in a future 
edition once available evidence has been systematically reviewed. For 
biological control with larvivorous fish, the evidence base was found to be 
insufficient to support a recommendation for use as an intervention with 
public health impact.
M
AL
AR
IA
 V
EC
TO
R 
CO
NT
RO
L 
G
UI
DE
LI
NE
S
xv
Personal protection measures considered in development of the 
Guidelines were topical repellents, insecticide-treated clothing and 
indoor spatial/airborne repellents. The evidence base for these 
interventions was deemed insufficient to support their recommendation 
for use as interventions with public health value. However, due to the likely 
protection of users from mosquito bites and, in turn, malaria infection, the 
use of topical repellents and insecticide-treated clothing are considered 
to be public health interventions. WHO is investigating a process and 
associated evaluation endpoints to develop evidence-based policy 
recommendations on these and other public health interventions designed 
to provide personal protection.
Space spraying (i.e. insecticide applied through: thermal fogging; cold 
aerosol distribution by handheld or backpack sprayers, ground vehicles 
or aerial means; or repetitious spraying by two or more sprays in quick 
succession) should not be undertaken for malaria vector control. The 
evidence base for housing improvement as an approach for malaria 
prevention and control is currently under review, and recommendations in 
this area will be included in an update to the Guidelines. 
xvi
1 Statements reflecting consensus of the guidelines development group, but not supported by a systematic 
evidence review.
Recommendations
Malaria vector control
MALARIA BURDEN REDUCTION AND ELIMINATION
Priority should be given to delivering either ITNs or IRS at high coverage 
and to a high standard, rather than introducing the second intervention as 
a means to compensate for deficiencies in the implementation of the first 
intervention. 
Conditional recommendation against combining the core interventions to 
reduce morbidity and mortality, moderate-certainty evidence
Universal coverage with effective vector control using a core intervention 
(ITNs or IRS) is recommended for all populations at risk of malaria in most 
epidemiological and ecological settings. The population at risk of malaria 
may increase or decrease as a result of changes in malariogenic potential 
of a given geographical area. 
Good practice statement 1
Once high coverage with one core intervention has been achieved, 
programmes may consider deploying the other core intervention as an 
approach to prevent, manage and mitigate insecticide resistance. The 
ITN and IRS products selected for co-deployment must not contain the 
same insecticide class(es). For instance, IRS with a pyrethroid should not 
be deployed in the same households or areas as ITNs. The decision to 
deploy a second core vector control intervention should only be taken after 
conducting a prioritization analysis across malaria interventions, not just 
vector control, to ensure maximum impact of any additional resources.
Good practice statement
Once high coverage with a core intervention has been achieved, 
recommended supplementary interventions with proven public health value 
may be deployed in specific settings and circumstances. The decision to
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2 The minimum size of an area is determined by the availability of reliable disaggregated disease 
surveillance data and feasibility for making decisions on vector control implementation. The area is not 
necessarily based on administrative boundaries. 
3 Defined as 10–80% mosquito mortality in standard WHO susceptibility tests or CDC bottle bioassays
deploy a supplementary vector control intervention should only be taken 
after conducting a prioritization analysis across malaria interventions, not 
just vector control, to ensure maximum impact of any additional resources.
Good practice statement
In areas2 with ongoing local malaria transmission (irrespective of both 
the pre-intervention and current level of transmission), vector control 
interventions should not be scaled back. Universal coverage with effective 
malaria vector control of all inhabitants of such areas should be pursued 
and maintained.
Good practice statement
In areas2 where transmission has been interrupted, the scale-back of vector 
control should be based on a detailed analysis that includes assessment 
of the receptivity and vulnerability, active disease surveillance system, and 
capacity for case management and vector control response.
Good practice statement
Core interventions
INSECTICIDE-TREATED NETS
Pyrethroid-only LLINs prequalified by WHO are recommended for 
deployment as a core intervention in all malaria-endemic settings.
Strong recommendation as an intervention with public health value, high-
certainty evidence
Pyrethroid-PBO nets prequalified by WHO are conditionally recommended 
for deployment instead of pyrethroid-only LLINs where the principal 
malaria vector(s) exhibit pyrethroid resistance that is: a) confirmed, b) of 
intermediate level,3 and c) conferred (at least in part) by a monooxygenase-
based resistance mechanism, as determined by standard procedures.
Conditional recommendation as an intervention with public health value, 
moderate-certainty evidence
xviii
Recipients of ITNs should be advised (through appropriate communication 
strategies) to continue using their nets beyond the three-year anticipated 
lifespan of the net, irrespective of the condition of the net, until a 
replacement net is available.
Good practice statement
Recipients of ITNs should be advised (through appropriate communication 
strategies) to continue using their net even if it is damaged or contains holes, 
irrespective of the age of the net, until a replacement net is available.
Good practice statement
Recipients of ITNs should be advised (through appropriate  
communication strategies) not to dispose of their nets in any water body, 
as the residual insecticide on the net can be toxic to aquatic organisms 
(especially fish).
Good practice statement
Old ITNs should only be collected where there is assurance that: i) 
communities are not left uncovered, i.e. new ITNs are distributed to replace 
old ones; and ii) there is a suitable and sustainable plan in place for safe 
disposal of the collected material.
Good practice statement
If ITNs and their packaging (bags and baling materials) are collected, 
the best option for disposal is high-temperature incineration. They should 
not be burned in the open air. In the absence of appropriate facilities, 
they should be buried away from water sources and preferably in non-
permeable soil.
Good practice statement
INDOOR RESIDUAL SPRAYING
IRS deploying a product prequalified by WHO is recommended as a 
core intervention in all malaria-endemic settings. DDT has not been 
prequalified; it may be used for IRS if no equally effective and efficient 
alternative is available, and if it is used in line with the Stockholm 
Convention on Persistent Organic Pollutants.
Strong recommendation as an intervention with public health value, low-
certainty evidence
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Supplementary interventions
LARVICIDING
The regular application of biological or chemical insecticides to water 
bodies (larviciding) is recommended as a supplementary intervention in 
areas where high coverage with a core intervention has been achieved, 
where aquatic habitats of the principal malaria vector(s) are few, fixed and 
findable, and where its application is both feasible and cost-effective.
Conditional recommendation as an intervention with public health value, low-
certainty evidence
Personal protection measures
TOPICAL REPELLENTS
Deployment of topical repellents is not recommended as an intervention 
with public health value; however, topical repellents may be beneficial as 
an intervention to provide personal protection. 
Conditional recommendation against deployment as an intervention with 
public health value, low-certainty evidence
INSECTICIDE-TREATED CLOTHING
Use of insecticide-treated clothing is not recommended as an intervention 
with public health value; however, insecticide-treated clothing may be 
beneficial as an intervention to provide personal protection in specific 
population groups.
Conditional recommendation against deployment as an intervention with 
public health value, low-certainty evidence
xx
Other interventions
SPACE SPRAYING
Space spraying should not be undertaken for malaria control, and IRS or 
ITNs should be prioritized instead.
Conditional recommendation against deployment, very low-certainty evidence
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1. Introduction
1.1 BACKGROUND
Malaria remains an important cause of illness and death in children 
and adults throughout the world, with 87 countries reporting one or 
more cases of malaria in 2017. Malaria control requires an integrated 
approach, including prevention (with an emphasis on vector control, plus 
chemoprevention), early diagnosis and prompt effective treatment. The 
WHO Guidelines for the treatment of malaria were first developed in 2006 
and have been revised periodically, with the most recent edition published 
in 2015. To date there has been no equivalent comprehensive guidelines 
document on malaria vector control.
WHO guidelines contain recommendations on clinical practice or public 
health policy intended to guide end-users as to the individual or collective 
actions that can or should be taken in specific situations to achieve the 
best possible health outcomes. Such recommendations are also designed 
to help the user to select and prioritize interventions from a range of 
potential alternatives. The recommendations in this 1st edition of the 
Guidelines for malaria vector control are based on a firm evidence base 
for certain interventions, whereas for other interventions, major information 
gaps necessitated formulation of guidance based on expert opinion. 
The Guidelines will therefore remain under regular review; updates are 
envisioned on an ongoing basis as new evidence becomes available. 
The recommendations and their rationale presented in the main body of 
this document are brief so as to facilitate quick reference. More detail on 
the underlying evidence base is provided in a series of annexes.
1.2 OBJECTIVES
The objectives of the Guidelines are:
1. to provide evidence-based recommendations on the appropriate 
choice(s) of vector control options for malaria prevention and control;
2. to inform and guide technical decisions on the effective implementation 
of each of the vector control options currently available for malaria 
prevention and control;
23. to support the development by WHO Member States of evidence-
based national malaria vector control policies and strategies;
4. to facilitate uptake of WHO guidance by bringing together a large 
number of existing guidance documents on malaria vector control into 
one document; and
5. to inform a research agenda to support revision of the Guidelines by 
identifying gaps in evidence that are constraining the development of 
guidance or weakening current recommendations. 
1.3 SCOPE
The Guidelines provide evidence-based recommendations pertaining to 
vector control tools, technologies and approaches (collectively termed 
“interventions”) that are currently available for malaria prevention and 
control, and for which sufficient evidence on their efficacy is available to 
support systematic reviews. For areas where evidence is currently weak 
or absent, the development of guidance relies on expert opinion to a 
considerable extent. The vector control recommendations presented in 
the Guidelines are based on a consideration of the evidence gained from 
randomized controlled trials (RCTs) and other types of trials and studies, 
as well as the technical knowledge and experience of the Guidelines 
Development Group, Guidelines Steering Group and External Review 
Group (the latter of which was comprised of members of the Malaria Policy 
Advisory Committee (MPAC)) (Annex 1). 
The Guidelines are intended to provide an underlying framework for the 
design of effective, evidence-based national vector control strategies and 
their adaptation to local disease epidemiology and vector bionomics. 
1.4 OUTCOMES
The Guidelines commence by providing general recommendations on 
malaria vector control, followed by more specific recommendations on 
individual interventions and good practice statements on their deployment. 
The interventions are divided into categories of core, supplementary, 
personal protection, and other interventions. Core interventions are those 
that have demonstrated public health value and are broadly applicable 
for populations at risk of malaria in most epidemiological and ecological 
settings. Supplementary interventions are those that are applicable for 
specific populations, situations or settings and hence are not broadly 
applicable. Personal protection measures have the primary function of 
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protecting individual users, although they may have some as yet unproven 
public health value. Other interventions with potential public health value 
are also presented. For some interventions, the evidence base is currently 
under review. The outcome of these revisions will inform the formulation of 
revised or new recommendations, to be incorporated into the Guidelines.
1.5 TARGET AUDIENCE
The Guidelines have been developed primarily for programme managers, 
health professionals, environmental health services professionals, 
procurement agencies and others responsible for implementing and 
financing malaria vector control in malaria-endemic countries. The 
Guidelines are also intended for use by international development 
partners, donors and funding agencies in order to support decision-
making on the selection of interventions and procurement of appropriate 
vector control products. They are also intended to guide researchers and 
those interested in the outcomes of research to address the evidence gaps 
that are constraining the development of guidance or weakening current 
recommendations. 
1.6 FUNDING
The Guidelines, developed by the WHO Global Malaria Programme, were 
funded through an umbrella grant agreement with the Bill & Melinda 
Gates Foundation. No other external source of funding either from bilateral 
technical partners or from industry was solicited or used.
1.7 MANAGEMENT OF CONFLICTS OF INTEREST
All members of the Guidelines Development Group and the Expert Review 
Group made declarations of interest, which were managed in accordance 
with standard WHO procedures and cleared by the Office of Compliance, 
Risk Management and Ethics. The WHO Guidelines Steering Group and 
the Chair of the Guidelines Development Group were satisfied that there 
had been a transparent declaration of interests. No case necessitated 
the exclusion of any Guidelines Development Group or Expert Review 
Group members. No potential conflicts of interest that could have 
compromised any individual member’s stance on equity and human rights 
were identified. The members of the Guidelines Development Group, the 
Guidelines Steering Group and the External Review Group, as well as a 
summary of the declarations of interest are listed in Annex 1.
41.8 METHODS USED TO FORMULATE 
RECOMMENDATIONS 
The Guidelines were prepared in accordance with latest standard WHO 
methods for guideline development (3). Types of outcome measures 
assessed in the evidence reviews included: rate of all-cause child mortality; 
incidence rate of malaria; incidence rate of severe malaria episodes; 
rate of clinical malaria; rate of uncomplicated episodes of P. falciparum; 
malaria incidence; parasite prevalence (also specifically P. falciparum 
and P. vivax prevalence); anaemia prevalence; entomological inoculation 
rate (EIR); density of immature vector stages; and, number of larval sites 
positive for immature vector stages. 
The WHO guideline development process involves planning; conducting 
a ‘scoping’ and needs assessment; establishing an internal WHO 
Guidelines Steering Group and an external Guidelines Development 
Group; formulating key questions in PICO format; commissioning evidence 
reviews; applying Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) to the certainty of evidence; and making 
recommendations. This methodology (see Annex 2) ensures that the link 
between the evidence base and the recommendations is transparent.
The WHO Guidelines Steering Group was responsible for drafting the scope 
of the Guidelines and preparing the planning proposal, formulating key 
questions, identifying potential members for the Guidelines Development 
Group, obtaining declarations of interest from Guidelines Development 
Group members, managing any conflicts of interest, and submitting the 
finalized planning proposal to the Guidelines Review Committee for review.
The Guidelines Development Group was an external body whose central 
task was to develop the evidence-based recommendations contained in 
the Guidelines. The specific tasks of the Guidelines Development Group 
included:
• providing inputs as to the scope of the Guidelines;
• assisting the Guidelines Steering Group in developing the key questions 
in PICO format;
• choosing and ranking priority outcomes to guide the evidence reviews 
and focus the recommendations;
• examining the GRADE evidence profiles or other assessments of 
the certainty of evidence used to inform the recommendations, and 
providing input where necessary;
M
AL
AR
IA
 V
EC
TO
R 
CO
NT
RO
L 
G
UI
DE
LI
NE
S
5
• interpreting the evidence, with explicit consideration of the overall 
balance of benefits and harms;
• formulating recommendations, taking into account benefits, harms, 
values and preferences, feasibility, equity, acceptability, resource 
requirements and other factors, as appropriate;
• identifying methodological issues and evidence gaps, and providing 
guidance on how to address these; and 
• reviewing and approving the final document prior to submission to the 
Guidelines Review Committee. 
The Guidelines Development Group established for these Guidelines 
consisted of 13 members that included: relevant technical experts; intended 
end-users (programme managers and health professionals responsible 
for adopting, adapting and implementing the Guidelines); other 
representatives from malaria-endemic countries; and experts in assessing 
evidence and developing evidence-based guidelines. The Chair of the 
Guidelines Development Group and several of its members had expertise 
in ensuring that equity, human rights, gender and social determinants are 
taken into consideration in efforts to improve public health outcomes. 
The Guidelines Development Group used GRADEPro software 
(https://gradepro.org/), specifically the interactive Evidence-to-
Decision Framework, to assist in the process of evidence review and 
recommendation-setting. The Evidence-to-Decision Framework considers 
12 criteria to arrive at a recommendation for or against an intervention; 
these are listed in Annex 3 along with accompanying descriptions.
The Evidence-to-Decision Framework summaries for each of the 
recommendations contained in the Guidelines are presented alongside 
the GRADE tables in Annex 4. Selected external reviewers, consisting of 
persons interested in the subject of the Guidelines and individuals who 
would be affected by the recommendations, conducted a peer review of 
the draft Guidelines document to inform revisions prior to its submission to 
the Guidelines Review Committee for approval.
Sources of evidence
Following the Guidelines scoping meeting, the Cochrane Infectious 
Diseases Group (CIDG) at the Liverpool School of Tropical Medicine in 
Liverpool, United Kingdom of Northern Ireland and Great Britain was 
commissioned to undertake systematic reviews and assess the certainty of 
evidence for each priority question. This included new systematic reviews 
on the combined deployment of IRS with ITNs; and space spraying. Existing 
6systematic reviews covering larviciding, the deployment of larvivorous 
fish, and ITNs were updated. GRADE tables for IRS were produced based 
on the existing 2010 review (as no new studies have been published since 
2010), and an ongoing systematic review on topical insect repellents was 
completed.
The inclusion criteria for the reviews were RCTs and quasi-experimental 
designs, including controlled before-and-after studies, interrupted time 
series (controlled and uncontrolled), and stepped wedge designs. All 
reviews and updates involved searches of the CIDG Specialized Register; 
the Cochrane Central Register of Controlled Trials, the Cochrane Library; 
MEDLINE (PubMed); Embase (OVID); CABS Abstracts (Web of Science); and 
LILACS (BIREME). The WHO International Clinical Trials Registry Platform, 
ClinicalTrials.gov and the ISRCTN registry were also searched to identify 
trials in progress. A combination of controlled vocabulary terms and free-
text terms was used, including: malaria, mosquito, Anopheles, insecticides, 
bednets, ITN, IRS, and additional terms for the interventions specific to each 
review. Detailed search terms are reported in the Appendix of each review 
protocol, as published in the Cochrane Database of Systematic Reviews. 
Searches were not limited by time or publication language. Reference lists 
of all included studies were reviewed and the “similar articles” function in 
MEDLINE was used to see if additional studies could be identified.
Each search was independently assessed by two review authors. Included 
studies were described, assessed, and data presented as specified in 
the protocol using Covidence and Review Manager 5 software. GRADE 
formulation and application of subgroup analysis was carried out by the 
review author teams, with oversight from the CIDG editorial team, including 
the Co-ordinating Editor, three Editors, and the SIDG Statistician. 
In formulating its recommendations, the Guidelines Development Group 
also considered additional evidence that was deemed unsuitable for 
inclusion and analysis under the Cochrane systematic review process, 
particularly in developing the Evidence-to-Decision Frameworks 
(Annex 4). IRS is a core intervention for malaria prevention and control 
that has been used successfully in malaria-endemic countries for decades, 
but is an intervention for which few RCTs have been conducted. Therefore, 
the availability of data suitable for use in a Cochrane-style meta-analysis 
is limited. A separate systematic review of the large body of evidence 
generated from the IRS implementation trials and from national control 
programmes will be conducted to further strengthen the evidence base to 
support recommendations pertaining to this core intervention.
Pre-existing WHO recommendations and guidance relevant to malaria, 
and specifically to vector control, were also reviewed and in some cases 
revised by the Guidelines Development Group.
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Certainty of evidence
The certainty of evidence from the systematic reviews was assessed for 
each outcome and rated on a four-point scale (Table 1), after considering 
the risk of bias (including publication bias) and the consistency, directness 
and precision of the effect estimates. The terms used in the certainty 
assessments refer to the Guidelines Development Group’s level of 
confidence in the estimate of effect (and not to the scientific quality of the 
investigations reviewed).
TABLE 1
The four classes of certainty of evidence used in GRADE
CERTAINTY OF EVIDENCE INTERPRETATION
High
The Group is very confident in the estimate of effect and 
considers that further research is very unlikely to change this 
confidence.
Moderate
The Group has moderate confidence in the estimate of 
effect and considers that further research is likely to have an 
important impact on that confidence and may change the 
estimate.
Low
The Group has low confidence in the estimate of effect 
and considers that further research is very likely to have an 
important impact on that confidence and is likely to change 
the estimate.
Very Low The Group is very uncertain about the estimate of effect.
Presentation of evidence and link to recommendations
For ease of reference, the recommendations are presented in a simplified 
descriptive form in the main document. The recommendations are shown 
in boxes in each respective section (light green); an evidence box (light 
grey) is also presented for each recommendation. The complete GRADE 
tables and additional references are provided in Annex 4.
Formulation of recommendations
The systematic reviews, GRADE tables and other relevant materials 
were provided to all members of the Guidelines Development Group. 
Recommendations were formulated after considering the certainty of 
evidence, the balance of benefits and harms, values and preferences, and 
the feasibility of the intervention (Table 2). Values and preferences were 
taken into account through discussions on the relative value beneficiaries 
place on the outcomes of the intervention, and on the relative acceptability 
8of the intervention to the beneficiaries. Although cost is a critical factor in 
setting national vector control policies and was broadly considered in the 
recommendation formulation process, explicit analyses of the costs and 
cost-effectiveness of the various interventions did not form part of the 
Cochrane reviews conducted for this 1st edition of the Guidelines. Expanded 
evidence-based recommendations on resource implications will be 
developed and incorporated into a revised version of the Guidelines. 
The Guidelines Development Group discussed the proposed wording 
of each recommendation at in-person meetings and through e-mail 
correspondence and teleconferencing, and rated the strength of each 
recommendation in accordance with the four-point scale presented in 
Table 1. The guideline development process aimed to generate group 
consensus; voting on specific points was available as an option to finalize 
recommendations on which no consensus could be reached. The final 
draft was circulated to the Guidelines Development Group and the 
External Review Group (Annex 1). Comments from external reviewers were 
incorporated into the revised Guidelines as appropriate. 
TABLE 2
Factors other than certainty of evidence considered in the formulation 
of recommendations
FACTORS CONSIDERED RATIONALE
Balance of benefits and 
harm
The more the expected benefits outweigh the expected 
risks, the more likely it is that a strong recommendation 
will be made. When the balance of benefits and harm is 
likely to vary by setting or is a fine balance, a conditional 
recommendation is more likely. 
Values and preferences If the recommendation is likely to be widely accepted or highly valued, a strong recommendation is more likely. 
Feasibility
If an intervention is achievable in the settings in which the 
greatest impact is expected, a strong recommendation is 
more likely. 
Types of guidance
Two types of guidance are presented in the Guidelines.
• Intervention recommendations: These recommendations were 
formulated by the panel using the GRADE approach, supported by 
systematic reviews of the evidence, with formal assessment of the 
certainty of evidence. 
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• Good practice statements: These statements reflect a consensus 
among the panel that the net benefits of adherence to the statement 
are large and unequivocal, and that the implications of the statement 
are common sense. These statements have usually been taken 
or adapted from existing recommendations or guidance initially 
developed through broad consultation, such as through the WHO 
Technical Expert Group on Malaria Vector Control (VCTEG) or MPAC. 
These statements are made to reinforce the basic principles of good 
management practice for implementation. 
Strength of recommendations
Each intervention recommendation was classified as strong or conditional 
using the criteria in Table 3:
TABLE 3
Classification of recommendations
STRENGTH OF 
RECOMMENDATION
INTERPRETATION
FOR POLICY-
MAKERS
FOR PROGRAMME 
MANAGERS / 
TECHNICIANS
FOR END-USERS
Strong
This 
recommendation 
can be adopted 
as policy in most 
situations.
Most individuals 
should receive the 
recommended 
intervention.
Most people in 
your situation 
would want the 
recommended 
intervention.
Conditional
Substantial debate 
is required at 
national level, with 
the involvement 
of various 
stakeholders.
Some individuals 
should receive the 
recommended 
intervention, if 
certain criteria are 
met.
Some people in 
your situation 
would want the 
recommended 
intervention, if 
certain criteria are 
met.
1.9 DISSEMINATION
The Guidelines will be published electronically in PDF format on the WHO 
website. Using electronic rather than hardcopy versions is a less expensive 
and faster way to provide up-to-date guidance to Member States and 
their implementing partners. The English language version will be made 
available first, with French and Spanish translations to follow soon after. 
WHO Headquarters will work closely with its Regional and Country Offices 
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to ensure the wide dissemination of the Guidelines to all malaria-endemic 
countries. The Guidelines will also be disseminated through webinars and 
through regional, subregional and country meetings, as appropriate. 
Member States will be supported by WHO in the development and update 
of national strategies based on these Guidelines.
1.10 UPDATING
Updates to the Guidelines will be undertaken as soon as possible once 
new evidence for interventions with an existing policy recommendation 
becomes available, or as the Vector Control Advisory Group (VCAG) 
assesses new vector control tools, technologies or approaches, their public 
health value is validated and a WHO policy recommendation supporting 
their deployment has been formulated (4). Periodic monitoring and 
evaluation of the use of the Guidelines by Member States will be conducted 
by means of malaria programme reviews and other technical support 
missions.
1.11 USER FEEDBACK
User feedback on the 1st edition of the Guidelines will be collected as part 
of all dissemination activities both informally and by directing users to the 
generic WHO GMP email address: vcguidelines@who.int. In addition, an 
online survey will be conducted to capture user experiences prior to major 
revisions to the Guidelines.
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2. Malaria and related 
entomological and 
vector control concepts
2.1 ETIOLOGY
Malaria is a life-threatening disease caused by the infection of red 
blood cells with protozoan parasites of the genus Plasmodium that are 
transmitted to people through the bites of infected female Anopheles 
mosquitoes. Four species of Plasmodium (P. falciparum, P. vivax, 
P. malariae and P. ovale) most commonly infect humans. P. falciparum 
and P. vivax are the most prevalent species and P. falciparum is the most 
dangerous. A fifth species, P. knowlesi (a species of Plasmodium that 
primarily infects non-human primates) is increasingly being reported in 
humans inhabiting forested regions of some countries of South-East Asia 
and the Western Pacific regions, and in particular on the island of Borneo. 
The intensity of transmission depends on factors related to the parasite, 
the vector, the human host and the environment. Transmission tends to be 
more intense in places where the mosquito lifespan is longer and where 
the females prefer to bite humans rather than other animals. The survival 
and longevity of female mosquitoes is of critical importance in malaria 
transmission, as the malaria parasite generally requires a period of  
7–10 days to develop inside the mosquito into a form that is infective to 
humans. Female mosquito longevity is dependent on intrinsic, genetic 
factors, as well as on environmental factors including temperature and 
humidity. The strong human biting habit of the African vector species is one 
of the reasons why approximately 90% of the world’s malaria cases occur 
in Africa.
The intensity of malaria transmission in a given geographical area has 
important consequences for the pattern and distribution of clinical disease 
in the human population and influences the choice of vector control 
interventions. Under conditions of ‘stable malaria transmission’, where 
populations are continuously exposed to a high frequency of malarial 
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inoculation,4 partial immunity to clinical disease is acquired in early 
childhood which results in a reduced risk of developing severe malaria in 
older children. In situations where transmission is stable, clinical disease 
is confined mainly to young children before they have acquired partial 
immunity. These children may develop high parasite densities that can 
progress very rapidly to severe malaria. By contrast, adolescents and 
adults are partially immune and consequently seldom suffer clinical 
disease in these endemic settings, although they may continue to have 
low densities of parasites in their blood and are capable of infecting 
mosquitoes. This is the situation in many parts of sub-Saharan Africa. 
Immunity is modified during pregnancy, such that pregnant women, 
especially those undergoing their first pregnancy, are at increased risk of 
both infection and severity of infection. Immunity is gradually lost, at least 
partially, when individuals move out of an endemic area for long periods of 
time (usually many years).
In areas of ‘unstable malaria transmission’, which prevail in much of Asia, 
Latin America and the remaining parts of the world where malaria is 
endemic, the intensity of malaria transmission fluctuates widely by season 
and year and over relatively small distances. P. vivax is an important cause 
of malaria in these regions. The generally low level of transmission retards 
the acquisition of immunity such that people of all ages – adults and 
children alike – suffer from acute clinical malaria, with a significant risk that 
the disease will progress to severe malaria if left untreated. Epidemics may 
occur in areas of unstable malaria transmission when the EIR increases 
rapidly following a sudden increase in vector population density or 
longevity. Epidemics manifest as a very high incidence of malaria in all age 
groups. During epidemics, severe malaria is common if prompt, effective 
treatment is not widely available. Non-immune travellers to a malaria-
endemic area are at particularly high risk of severe malaria if their infection 
is not detected promptly and treated effectively.
2.2 VECTORS AND THEIR BEHAVIOUR AND 
DISTRIBUTION
Malaria is transmitted through the bites of infective female Anopheles 
mosquitoes. There are more than 400 different species of Anopheles 
mosquito, of which around 40 are malaria vectors of major importance. 
Annex 5 presents a list of principal vector species by WHO region, 
along with a brief description of the key ecological and behavioural 
characteristics relevant to control.
4 Generally defined as an entomological inoculation rate (EIR) that exceeds 10 infective bites per person per 
year.
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Anopheles mosquitoes lay their eggs in water. The eggs hatch to produce 
larvae, which undergo several moults before emerging from the pupal 
stage as adult mosquitoes. Different species of Anopheles mosquito have 
their own preferred aquatic habitats; for example, some prefer small, 
shallow collections of fresh water such as puddles and animal hoof prints, 
whereas others prefer large, open water bodies including lakes, swamps 
and rice fields.
Immediately after emerging from the pupal stage, mosquitoes rest on the 
water surface until their wings have fully expanded and hardened. After 
taking an initial meal of plant nectar, female mosquitoes seek a blood 
meal as they require protein to develop their eggs. In the majority of 
species of Anopheles, the females feed on warm-blooded animals, usually 
mammals. Different mosquito species demonstrate preferences for feeding 
on animals (zoophily) or on humans (anthropophily); however, these 
preferences are not absolute and females may take a blood meal from a 
non-preferred host when these are present in the area. Blood-feeding can 
take place inside human habitations (endophagy) or outdoors (exophagy), 
depending on the mosquito species. Several factors have been implicated 
in the attraction of female mosquitoes to a host, including exhaled 
carbon dioxide, lactic acid, host odours, warmth and moisture. Different 
host individuals may be more or less attractive to mosquitoes than other 
individuals of the same species.
Female Anopheles mosquitoes feed predominantly at night, although 
some species may bite during the day in heavily shaded conditions, and 
some exhibit a peak in biting activity in the early evening or early morning. 
The interplay between the peak biting time of the Anopheles vector 
and the activity and sleeping patterns of the human host has important 
consequences for malaria transmission and the choice of appropriate 
vector control interventions. 
After blood-feeding, female mosquitoes rest in order to digest the blood 
meal and mature their eggs. Female mosquitoes may rest indoors 
(endophily) or outdoors (exophily), and this depends on innate species 
preferences as well as the availability of suitable resting sites in the local 
environment. The mosquitoes’ choice of post-feeding resting site also has 
major implications for the selection of control interventions. 
It is important to note that while an individual species of Anopheles will 
characteristically exhibit certain biting and resting behaviours, these are not 
absolute; subpopulations and individuals may exhibit different behaviours 
depending on a combination of intrinsic genetic factors, availability of 
preferred hosts and availability of suitable resting sites. Environmental 
and climatic factors, including rainfall, moonlight, wind speed, etc., as well 
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as the deployment of vector control interventions can all influence biting 
and resting behaviours. For example, the highly efficient African malaria 
vector Anopheles gambiae s.s. is generally considered to be human-biting, 
indoor-biting and indoor-resting, but it can also exhibit more zoophilic and 
exophagic tendencies. Anopheles arabiensis is a species that generally 
exhibits an outdoor biting and resting habit, but may exhibit indoor biting 
and resting tendencies, depending on the availability of alternative hosts.
Accurate species identification is crucial for all studies and surveillance 
activities on field populations of vectors. Many of the vectors belong to 
species complexes and require advanced molecular analyses for species 
identification, necessitating appropriate laboratory resources. Without 
accurate species identification, data collected on behaviour, distribution 
and infection rates for decision-making by control programmes will have 
limited use. 
2.3 BACKGROUND AND RATIONALE FOR VECTOR 
CONTROL
The role of arthropods in the transmission of diseases to humans was first 
elucidated in the late 19th and early 20th centuries. Since effective vaccines 
or drugs were not always available for the prevention or treatment of these 
diseases, control of transmission often had to rely principally on control of 
the vector. Early control activities included the screening of houses, the use 
of mosquito nets, the drainage or filling of swamps and other water bodies 
used by insects for breeding, and the application of oil or Paris green to 
breeding places. Following the discovery of the insecticidal properties 
of dichlorodiphenyltrichloroethane (DDT) in the 1940s and subsequent 
discovery of other insecticides, the focus of malaria vector control shifted to 
the deployment of insecticides to target both the larval and adult stages of 
mosquito vectors. 
Nowadays, it is well established that effective vector control programmes 
can make a major contribution towards advancing human and economic 
development. Aside from direct health benefits, reductions in vector-
borne diseases enable greater productivity and growth, reduce household 
poverty, increase equity and women’s empowerment, and strengthen 
health systems (6). Despite the clear evidence in broad support of vector 
control efforts, the major vector-borne diseases combined still account 
for around 17% of the estimated global burden of communicable diseases, 
claiming more than 700 000 lives every year (7). Recognizing the great 
potential to enhance efforts in this area, WHO led the development of 
the Global vector control response 2017–2030, which is outlined in the 
subsequent section.
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The control of malaria, unlike that of most other vector-borne diseases, 
has seen a major increase in financial resources since 2000, leading to a 
significant reduction in the global burden.  Between 2000 and 2015, the 
infection prevalence of P. falciparum in endemic Africa was halved and the 
incidence of clinical disease fell by 40% (8). Malaria control interventions 
averted an estimated 663 (credible interval (CI) 542–753) million clinical 
cases in Africa, with ITNs making the largest contribution (68% of cases 
averted). IRS contributed an estimated 13% (11–16%), with a larger 
proportional contribution where intervention coverage was high (7). 
Global vector control response 2017–2030
In 2017, the World Health Assembly welcomed the Global vector control 
response 2017–2030 (6) and adopted a resolution to promote an 
integrated approach to the control of vector-borne diseases. The approach 
builds on the concept of integrated vector management (IVM),5 but with 
renewed focus on improved human capacity at national and subnational 
levels, and an emphasis on strengthening infrastructure and systems, 
particularly in areas vulnerable to vector-borne diseases.
The vision of WHO and the broader infectious diseases community is a 
world free of human suffering from vector-borne diseases. The ultimate 
aim of the Global Vector Control Response is to reduce the burden and 
threat of vector-borne diseases through effective, locally adapted, 
sustainable vector control in full alignment with Sustainable Development 
Goal 3.3. The 2030 targets are: to reduce mortality due to vector-borne 
diseases globally by at least 75% (relative to 2016); to reduce case incidence 
due to vector-borne diseases globally by at least 60% (relative to 2016); and 
to prevent epidemics of vector-borne diseases in all countries. Detailed 
national and regional priority activities and associated interim targets for 
2017–2022 have also been defined. 
Effective and locally adaptive vector control systems depend on two 
foundational elements: i) enhanced human, infrastructural and health 
system capacity within all locally relevant sectors for vector surveillance 
and vector control delivery, monitoring and evaluation; and ii) innovation 
for the development of new tools, technologies and approaches and 
increased basic and applied research to underpin optimized vector control. 
Both elements are required to ensure the maximum impact of sustainable 
vector control by using an evidence-based approach to planning and 
implementation. 
5 WHO defines IVM as a rational decision-making process to optimize the use of resources for vector 
control.
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Effective and sustainable vector control is achievable only with sufficient 
human resources, an enabling infrastructure and a functional health 
system. Countries should conduct a vector control needs assessment (9) 
to help appraise current capacity, define the requisite capacity to conduct 
proposed activities, identify opportunities for improved efficiency in vector 
control delivery, and guide resource mobilization to implement the national 
strategic plan.
Action is required in four key areas (pillars) that are aligned with IVM: 
i) strengthening inter- and intra-sectoral action and collaboration;
ii) engaging and mobilizing communities; iii) enhancing vector surveillance 
and monitoring and evaluation of interventions; and iv) scaling up and 
integrating tools and approaches.
In some settings, vector control interventions can reduce transmission and 
disease burden of more than one disease. Examples include ITNs against 
malaria and lymphatic filariasis (in settings where Anopheles mosquitoes 
are the principal vector), IRS against malaria and leishmaniasis in India, 
and larval control for malaria and dengue vectors in cities with particular 
vector habitats. Approaches effective against Aedes spp. mosquitoes can 
have an impact on dengue, chikungunya, Zika virus disease and possibly 
yellow fever where their vectors and distributions overlap. However, 
programmes should avoid an approach that overlays multiple interventions 
to compensate for deficiencies in implementation of any one intervention; 
this may divert resources and attention away from reaching the full impact 
of existing interventions and lead to resource wastage.
The decision to use a vector control intervention in a particular setting 
or situation should be based on clear evidence of its epidemiological 
efficacy. Implementation must be to a high standard and aim to achieve 
and maintain universal coverage of at-risk populations. Covering at-
risk populations with evidence-based and cost-effective vector control 
interventions offers the greatest immediate opportunity to reduce infections 
and disease.
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3. Recommendations on 
malaria vector control
UNIVERSAL COVERAGE
Universal coverage with effective vector control using a core intervention 
(ITNs or IRS) is recommended for all populations at risk of malaria in most 
epidemiological and ecological settings. The population at risk of malaria 
may increase or decrease as a result of changes in malariogenic potential. 
Good practice statement
Universal health coverage means that all individuals and communities 
receive the health services they need without suffering financial hardship. 
It includes the full spectrum of essential, quality health services, from health 
promotion to prevention, treatment, rehabilitation and palliative care. In the 
context of malaria, universal coverage is defined as access to and use of 
appropriate interventions by the entire population at risk of malaria. 
The Global Technical Strategy for Malaria 2016-2030 states that it is 
essential for malaria programmes to “ensure universal access to malaria 
prevention, diagnosis and treatment” (Pillar 1). This strategy includes 
effective vector control as a major component, with a significant budgetary 
allocation.
The core vector control interventions applicable for all populations at 
risk of malaria in most epidemiological and ecological settings are: i) 
deployment of ITNs that are prequalified by WHO, which in many settings 
are LLINs; and ii) IRS with a product prequalified by WHO. The exception 
to this is DDT, which has not been prequalified. This insecticide may be 
used for IRS if no equally effective and efficient alternative is available, 
and if it is used in line with the Stockholm Convention on Persistent Organic 
Pollutants. Since 2000, 78% of the malaria clinical cases averted through 
interventions have been due to insecticidal vector control, namely through 
the widespread scale-up of ITNs and IRS. Universal coverage of vector 
control interventions is generally considered best practice to obtain optimal 
impact.  
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BOX 1. 
Summary of evidence from Cochrane systematic review
IRS compared to ITNs:
Two RCTs were included in the systematic review. Studies were 
conducted in an area with intense transmission (United Republic of 
Tanzania) and an area with unstable transmission (India).
• IRS may lead to a greater reduction in malaria incidence than 
ITNs in areas of intense transmission. 
(Rate Ratio: 0.88; 95% CI (0.78–0.98); one study; low certainty evidence)
• There may be little or no difference in parasite prevalence 
between IRS and ITNs in areas of intense transmission.
(Odds Ratio: 1.06; 95% CI (0.91–1.22); one study; low certainty evidence)
• IRS may reduce malaria incidence to a lesser extent than ITNs in 
areas of unstable transmission. 
(Rate Ratio: 1.48; 95% CI (1.37–1.60); one study; low certainty evidence)
• There may be little or no difference in parasite prevalence 
between IRS and ITNs in areas of unstable transmission.
(Odds Ratio: 1.70; 95% CI (1.18–2.44); one study; low certainty evidence)
In terms of the relative effectiveness of IRS compared to ITNs, there was 
only low certainty evidence available for areas of intense transmission and 
for areas with unstable transmission. It was therefore not possible to arrive 
at a definite conclusion on their comparative effectiveness. WHO therefore 
currently views these two core interventions as of equal effectiveness 
and there is no general recommendation to guide selection of one over 
the other. Preferences of national malaria programmes, beneficiaries 
or donors are usually based on operational factors, such perceived or 
actual implementation challenges (see Section 9) and the requirement for 
insecticide resistance prevention, mitigation and management (see 
Section 3.1). Financial considerations such as cost and cost-effectiveness 
are also major drivers of decision-making, and selection of malaria vector 
control interventions should thus be embedded into a prioritization process 
that considers the cost and effectiveness all available malaria interventions 
and aims at achieving maximum impact with the available resources. 
Evaluations of the relative cost and cost-effectiveness of ITNs and IRS are 
ongoing to inform revision of the Guidelines.
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CORE INTERVENTIONS
Priority should be given to delivering either ITNs or IRS at high coverage 
and to a high standard, rather than introducing the second intervention as 
a means to compensate for deficiencies in the implementation of the first 
intervention. 
Conditional recommendation against combining the core interventions to 
reduce morbidity and mortality, moderate-certainty evidence
BOX 2. 
Summary of evidence from Cochrane systematic review
IRS in addition to ITNs:
Four RCTs were included in the systematic review. Studies were 
conducted in Benin, Eritrea, Gambia and United Republic of 
Tanzania.
• IRS in addition to ITNs probably has little or no effect on malaria 
incidence compared to ITNs alone
(Rate Ratio: 1.17; 95% CI (0.92–1.46); two studies; moderate certainty 
evidence)
• IRS in addition to ITNs may have little or no effect on parasite 
prevalence compared to ITNs alone
(Odds Ratio: 1.04; 95% CI (0.73–1.48); four studies; low certainty evidence)
• It is unknown whether IRS in addition to ITNs reduces the EIR 
compared to ITNs alone
(Rate Ratio: 0.57; 95% CI (0.26–1.25); two studies; very low certainty 
evidence)
• IRS in addition to ITNs probably has little or no effect on anaemia 
prevalence compared to ITNs alone
(Odds Ratio: 1.04; 95% CI (0.83–1.30); two studies; moderate certainty 
evidence)
A review conducted in 2014 on the deployment of IRS in combination with 
ITNs (specifically pyrethroid-only LLINs) provided evidence that, in settings 
where there is high coverage with ITNs and where these remain effective, 
IRS may have limited utility in reducing malaria morbidity and mortality. 
WHO guidance was developed accordingly to emphasize the need for 
good-quality implementation of either ITNs or IRS, rather than deploying 
both in the same area (10). However, the combination of these interventions 
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may be considered for resistance prevention, mitigation or management 
should sufficient resources be available (see the following text and  
Section 3.1). Given the resource constraints across malaria endemic 
countries, the deployment of a second core vector control intervention 
on top of high coverage with an existing core vector control intervention 
should only be considered as part of a broader prioritization analysis 
aimed at achieving maximum impact with the available resources. In many 
settings, a switch from one to the other core intervention, rather than their 
combination, is likely to be the only financially feasible option 
COMBINATION OF INSECTICIDE-TREATED NETS AND INDOOR RESIDUAL 
SPRAYING
Once high coverage with one core intervention has been achieved, 
programmes may consider deploying the other core intervention as an 
approach to prevent, manage and mitigate insecticide resistance. The 
ITN and IRS products selected for co-deployment must not contain the 
same insecticide class(es). For instance, IRS with a pyrethroid should not 
be deployed in the same households or areas as ITNs. The decision to 
deploy a second core vector control intervention should only be taken after 
conducting a prioritization analysis across malaria interventions, not just 
vector control, to ensure maximum impact of any additional resources
Good practice statement
Insecticide resistance threatens the effectiveness of insecticidal 
interventions and hence is a key consideration in determining which 
vector control interventions to select to ensure impact of is maximised. 
One approach to the prevention, mitigation and management of 
vector insecticide resistance is the co-deployment (or combination) of 
interventions with different insecticides (see Section 3.1). Therefore, WHO 
guidance developed based on the 2014 review differentiated between the 
effect of combined interventions on malaria morbidity and mortality versus 
the utility of this approach in a resistance management strategy (9). 
A summary of the conclusions (with slight updates for clarity) used to 
develop the above recommendations is as follows:  
1. In settings with high ITN coverage where these remain effective, IRS 
may have limited utility in reducing malaria morbidity and mortality. 
However, IRS may be implemented as part of an insecticide resistance 
management (IRM) strategy in areas where there are ITNs (11).
2. If ITNs and IRS are to be deployed together in the same geographical 
location, IRS should be conducted with a non-pyrethroid insecticide. 
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3. Malaria control and elimination programmes should prioritize the 
delivery of ITNs or IRS at high coverage and to a high standard, rather 
than introducing the second intervention as a means to compensate for 
deficiencies in the implementation of the first intervention.
4. Evidence is needed to determine the effectiveness of combining IRS 
and ITNs in malaria transmission foci, including in low transmission 
settings. Evidence is also needed from different eco-epidemiological 
settings outside of Africa.
5. All programmes in any transmission setting that decide to prioritize the 
combined deployment of ITNs and IRS over other potential use of their 
financial resources should include a rigorous programme of monitoring 
and evaluation (e.g. a stepped wedge introduction of the combination) 
in order to confirm whether the additional inputs are having the 
desired impact. Countries that are already using both interventions 
should similarly undertake an evaluation of the effectiveness of the 
combination versus either ITNs or IRS alone.
These findings and conclusions were substantiated by a systematic review 
of the evidence (currently under peer review) that was conducted in 
preparing the Guidelines (12). However, subsequently released results from 
a study in one setting in Sudan showed that pyrethroid-only ITNs plus IRS 
with a non-pyrethroid reduced malaria incidence to a greater extent than 
ITNs alone in an area with pyrethroid resistance (13). An update to the 
systematic review will be required as additional evidence is currently being 
generated. 
Moreover, the approach of combining interventions for resistance 
management was developed largely based on experience with agricultural 
pest management, and the evidence base from public health remains 
weak.  
3.1 PREVENTION, MITIGATION AND MANAGEMENT 
OF INSECTICIDE RESISTANCE
Widespread and increasing insecticide resistance poses a threat to 
effective malaria vector control. Failure to prevent, mitigate and manage 
insecticide resistance is likely to eventually result in an increased burden 
of disease, potentially reversing some of the substantial gains made in 
controlling malaria over the last decade. 
The development of resistance in malaria vectors has so far been 
moderate overall. Monitoring insecticide resistance in malaria vectors 
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has revealed that, between 2010 and 2016, the frequency of pyrethroid 
resistance increased significantly in An. funestus s.l. (32% increase in 
resistance frequency), moderately in An. gambiae s.l. (13% increase) and 
only slightly in other malaria vectors (5% increase) (14). Between 2010 
and 2017, 68 of the 87 countries reporting one or more malaria cases in 
2017 have reported resistance to at least one insecticide, and 57 of those 
countries have reported resistance to two or more classes of insecticide. 
WHO maintains a global insecticide resistance database and an online 
mapping tool that consolidate information on the status of the insecticide 
susceptibility of Anopheles mosquitoes in malaria-endemic countries (15). 
To date, there is no evidence of operational failure of vector control 
programmes as a direct result of increasing frequency of pyrethroid 
resistance pyrethroid resistance (13, 16). Based on past experience, 
however, it is likely that operational failure will eventually occur if effective 
IRM strategies are not designed and implemented. Ideally, such strategies 
should be implemented before resistance arises. The overarching concepts 
of such resistance management strategies were outlined in the Global plan 
for insecticide resistance management in malaria vectors (GPIRM) in  
2012 (10). 
The GPIRM defines key technical principles for addressing insecticide 
resistance, as follows:
• Insecticides should be deployed with care and deliberation in order 
to reduce unnecessary selection pressure. Countries should consider 
whether they are using insecticides judiciously, carefully and with 
discrimination, and if there is a clear epidemiological benefit.
• Vector control programmes should avoid using a single class of 
insecticide everywhere and over consecutive years; instead, they 
should use rotations, mosaics, combinations of interventions, and 
mixtures (once available).
• Wherever possible, vector control programmes should diversify 
from pyrethroids in order to preserve their effectiveness. Although 
pyrethroids will continue to be used for ITNs in the near term, they 
should not generally be deployed for IRS in areas with ITNs.
• IRM principles and methods should be incorporated into all vector 
control programmes, not as an option, but as a core component of 
programme design.
• The agricultural sector should try to avoid using classes of insecticide 
that are widely used for public health and should collaborate with 
vector control authorities in an intersectoral approach.
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• Routine monitoring of insecticide resistance is essential to sustain the 
effectiveness of vector control interventions.
• The short-term additional costs of IRM should be balanced against 
the long-term potential public health impact and potential costs of 
insecticide resistance.
The subsequent section of the Guidelines builds on the original GPIRM 
recommendations in order to provide more detailed guidance on potential 
IRM approaches currently available to countries, as guided by resistance 
monitoring data (see Figure 1).
Approaches
Historically, the most common way insecticides have been deployed to 
control malaria vectors has been through ‘sequential use’.6  In essence, this 
is when a single insecticide class is used continuously or repeatedly until 
resistance has rendered it less effective or ineffective, after which a switch 
is made to an insecticide with a different mode of action to which there is 
no (or less) resistance. In theory, this may allow for an eventual switch back 
to the original insecticide class if resistance decreases to the point that it is 
no longer detectable by means of bioassays. Practical examples of such 
reversion are rare and tend to be short-lived when they do occur. This 
practice of sequential use, however, is not considered good practice for 
malaria vector control as it counters the proactive resistance management 
approach outlined in the GPIRM. Options to implement such a proactive 
IRM strategy are limited. 
All WHO prequalified ITNs contain a pyrethroid insecticide, either alone 
or combined with the synergist PBO, while one net contains a pyrethroid 
and a pyrrole (1).7 IRS formulations are prequalified from four out of five 
insecticide classes currently covered by a WHO policy recommendation. As 
of February 2019, no DDT product has been prequalified and none is under 
assessment.
Based on experience in agriculture, resistance management approaches 
have been proposed with the aim of preventing or delaying the emergence 
of resistance by removing selection pressure or by killing resistant 
6  This is likely due to: i) the limited number of insecticide classes historically available for malaria vector 
control, especially for ITNs; ii) the limited evidence base available to demonstrate impact of resistance 
and clear outcomes from resistance management approaches; and c) insufficient consideration given 
to the need to prevent or slow the development of resistance in order to preserve the effectiveness of 
available interventions.
7 A pyrrole is a broad-spectrum insecticide that acts on the insect’s stomach and through contact.
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mosquitoes. These include mixtures of insecticides, mosaic spraying, 
rotations of insecticides and deployment of multiple interventions in 
combination. 
• Mixtures are formulations that combine two or more insecticides with 
different modes of action. Mixtures are widely used as drug treatments 
in co-formulated combination therapy. Effective deployment of a 
mixture requires that the presence of resistance to all insecticides in 
the mixture is rare, so that any individual that survives exposure to 
one insecticide is highly likely to be killed by the other insecticide or 
insecticides. Ideally, all insecticides in a mixture should have a similar 
residual life and remain bioavailable over time; in practice, this is 
difficult to achieve, particularly for vector control products that are 
meant to last for a number of years, such as LLINs. An ITN product 
containing a pyrethroid and a pyrrole insecticide received a WHO 
interim recommendation after having been evaluated under the 
former WHOPES in phase I and II trials as a pyrethroid-only net (17); 
WHO will require data on the epidemiological impact of this product 
in order to enable assessment of its public health value and develop 
a WHO policy recommendation. ITNs with a pyrethroid and a juvenile 
hormone mimic8 have been developed, and one product is under WHO 
evaluation. A mixture of a pyrethroid and a neonicotinoid insecticide for 
IRS was recently prequalified by WHO.
• Rotations involve switching between insecticides with different modes 
of action at pre-set time intervals, irrespective of resistance frequencies. 
The theory is that resistance frequencies will decline (or at least not 
increase) during the period of non-deployment of insecticides with a 
specific mode of action. 
• Mosaics involve the deployment of insecticides of different modes of 
action in neighbouring geographical areas. The optimal spatial scale 
(size of areas) for mosaics has yet to be determined, and rotations are 
generally considered to be more practical and feasible. 
• Combinations expose the vector population to two classes of 
insecticides with differing modes of action through the co-deployment 
of different interventions in the same place. For instance, pyrethroid-
only LLINs combined with a non-pyrethroid IRS (where both are at 
high coverage) is a potential approach to IRM, although there is little 
evidence to indicate that such a combination of interventions will 
lead to additional epidemiological impact relative to one intervention 
deployed at high coverage (see above). 
8 A juvenile hormone mimic can inhibit development of adult characteristics or can interrupt reproductive 
maturation in adult insects.
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For public health vector control, there is still little evidence and no 
consensus on the best IRM approach or approaches to apply in a 
given situation. A 2013 review of experimental and modelling studies on 
insecticide, pesticide and drug resistance concluded that mixtures generally 
lead to the slowest evolution of resistance (18). However, more recently, 
an exploration of overlaps between agriculture and public health found 
that – owing to caveats and case specificity – there is only weak evidence 
of one IRM approach being better than another and that the standard 
practice of using insecticides until resistance emerges before switching to 
an alternative (i.e. sequential use) may be equally effective under certain 
circumstances. More research is thus needed to compare resistance 
management approaches in the field (19), and to improve understanding 
of the biological mechanisms that are likely to favour different approaches 
in different situations (20, 21).
Evidence-based planning
Given the heavy reliance on insecticidal interventions – primarily ITNs 
and IRS – insecticide resistance of local vectors is a key consideration in 
vector control planning and implementation. Ideally, IRM practices should 
be implemented as part of routine operations prior to the emergence of 
resistance, rather than waiting for resistance to develop and for control 
failure to be suspected or confirmed. However, pyrethroid resistance is 
common and widespread in major malaria vectors and resistance to the 
three other main insecticide classes used in malaria vector control has been 
detected across most regions of the world (13). A pragmatic approach 
must be taken that seeks to select appropriate vector control interventions 
based on the insecticide resistance profile of the major malaria vectors in 
the target area. To outline how resistance will be monitored and managed, 
countries should develop and implement national plans in accordance with 
the WHO Framework for a national plan for monitoring and management 
of insecticide resistance in malaria vectors (22). These plans should be 
revisited regularly to consider new information and to integrate new tools, 
technologies and approaches, once these are supported by WHO policy 
recommendations and have been prequalified. 
To assist countries in the selection of ITN or IRS product classes, Tables 
4 and 5 indicate whether the different product classes with a current 
WHO recommendation are considered optimal, acceptable or not 
recommended based on the resistance status (frequency), intensity and 
mechanisms of local vectors (23). One major caveat is that vector control 
interventions are seldom selected on the basis of resistance data alone. 
Such selection should also consider other influential factors specific to 
the local context, such as appropriateness of the intervention for housing 
structures, population acceptance or compliance, and available capacity 
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for deployment. Cost and availability of products can also be major factors 
affecting resistance management. Implementation of IRM should not come 
at the expense of reductions in vector control coverage for populations at 
risk of malaria.
The tables below define the suitability of different product classes based 
on available resistance information, but do not seek to prescribe the use of 
individual product classes or specific products. Where the combination of 
ITNs and IRS is appropriate, the selection of the non-pyrethroid IRS product 
should be guided by Table 5, based on insecticide resistance data. It is 
envisaged that as the public health value of additional interventions and 
product classes is validated and policy recommendations are developed, 
these tables will be updated accordingly through revision of the Guidelines. 
Modifications of methods to assess insecticide resistance9 may also be 
considered once the new evidence in this area becomes available.
To inform the decision-making process, resistance monitoring should 
ideally be conducted at sufficient sites that are representative of the  
eco-epidemiological setting(s) throughout the area for which intervention(s) 
are to be deployed. Resistance monitoring data should be collected for 
all principal malaria vectors at least annually; if data are available for 
multiple time points, the most recent should to be considered the most 
relevant. Resistance to each insecticide class being deployed or intended 
to be deployed should be tested so as to adequately guide selection of 
interventions and establish a baseline of information for new classes. 
However, implementation of resistance management or mitigation 
approaches need not wait until comprehensive data are available 
from resistance monitoring across the entire target area. Due to limited 
resources for monitoring (and potentially few mosquitoes for testing), there 
is likely to be the need to generalize data to larger areas of operational 
significance.
Examination of spatio-temporal trends in insecticide resistance is currently 
ongoing to inform the development of further guidance on the optimal 
frequency and extent of monitoring required to inform vector control 
decision-making. Further information on insecticide resistance monitoring 
and more broadly on entomological surveillance is included in the WHO 
reference manual on malaria surveillance, monitoring and evaluation, 
which outlines priority data across different transmission settings (24). 
9 Such as cone bioassays with different ITNs using local vector populations as a proxy for comparative 
bioefficacy
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TABLE 4. 
Selection of ITN product class based on outcomes from insecticide 
resistance monitoring in principal malaria vector(s), for areas in which 
ITNs are the core malaria vector control intervention
Options are indicated as: 
optimal (++), acceptable (+), or deployment not supported by data (-).
INTERVENTION PRODUCT CLASS
PYRETHROID INSECTICIDE(S) RESISTANCE
PRIMARY 
MEASURES SECONDARY MEASURES
Resistance status Resistance intensity
Resistance 
mechanism(s)
N
o 
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ed
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e1
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Resistance outcomes (see Figure 1 
and (22))
ITN
Pyrethroid-only 
nets ++ + + + + +
Pyrethroid plus 
synergist nets 
i.e. PBO nets
- 4 ++ 5 + + - 4 ++ 
Dark grey shading indicates that criteria specified for both resistance status and resistance mechanisms 
should be fulfilled for this to be considered optimal.
1  for all major vector species to all pyrethroid insecticides tested
2  for at least one major vector species to at least one pyrethroid insecticide
3  including moderate to high intensity where 10x intensity concentration has not been tested
4  may be considered acceptable instead of pyrethroid-only nets if this will not compromise coverage (e.g. 
total cost of the delivered PBO net is equal to or less than that of a pyrethroid-only net)
5  where % mosquito mortality in standard bioassays with the insecticide used on the ITN is 10–80%
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TABLE 5. 
Selection of IRS product class based on outcomes from insecticide 
resistance monitoring in principal malaria vector(s), for areas in which 
IRS is the core malaria vector control intervention
Options are indicated as: 
optimal (++), acceptable (+), or deployment not supported by data (-). 
INTERVENTION PRODUCT CLASS
INSECTICIDE RESISTANCE TO THE CLASS OF INSECTICIDE 
IN THE IRS PRODUCT
PRIMARY 
MEASURES SECONDARY MEASURES
Resistance status Resistance 
intensity
Resistance 
mechanism(s)
N
o 
co
nfi
rm
ed
 
re
sis
ta
nc
e 
to
 
in
se
ct
ic
id
e 
cl
as
s1
Co
nfi
rm
ed
 re
sis
ta
nc
e 
to
 in
se
ct
ic
id
e 
cl
as
s2
M
od
er
at
e 
or
 lo
w
 
in
te
ns
ity
 re
sis
ta
nc
e3
H
ig
h 
in
te
ns
ity
 
re
sis
ta
nc
e2
M
ec
ha
ni
sm
s 
kn
ow
n 
to
 c
on
fe
r r
es
ist
an
ce
 
to
 c
la
ss
 n
ot
 d
et
ec
te
d
M
ec
ha
ni
sm
s 
kn
ow
n 
to
 c
on
fe
r r
es
ist
an
ce
 
to
 c
la
ss
 d
et
ec
te
d
Resistance outcomes (see Figure 1 and 
(22))
IRS7
Organophosphate, 
organochlorine6, 
carbamate or 
pyrethroid formulations 
++ - - 4 - ++ - 5
Fast-acting insecticide 
formulations 
(with comparable 
entomological 
effectiveness to the 
above product class, i.e. 
neonicotinoids)
++ - - 4 - ++ - 5
1 for all major vector species to all insecticides tested of the insecticide class(es) used in the IRS product
2 for at least one major vector species to at least one insecticide of the insecticide class used in the IRS 
product
3 including moderate to high intensity where 10x intensity concentration has not been tested
4 may be considered acceptable if there is also confirmed resistance to all other insecticide classes in 
available IRS products
5 may be considered acceptable if mechanisms are detected that are known to confer resistance to all other 
insecticide classes in available IRS products
6 note that while DDT may have some utility for malaria vector control, as of 18 September 2018, there were 
no DDT IRS formulations prequalified by WHO
7 to be applied in rotation and/or mosaics with insecticide formulations of a different mode of action
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3.2 VECTOR CONTROL ACROSS DIFFERENT 
MALARIA TRANSMISSION SETTINGS
Understanding the degree of risk of malaria transmission in a given 
geographic area provides the foundation for the design of cost-effective 
intervention programmes to decrease malaria burden, eliminate 
transmission and prevent re-establishment of malaria. The risk of malaria 
transmission is the product of receptivity, vulnerability (i.e. importation risk) 
and mosquito infectivity, and is referred to as the malariogenic potential. 
The receptivity of an ecosystem to malaria transmission is determined by 
the presence of competent vectors, a suitable climate and a susceptible 
human population. Vulnerability refers to the rate of importation of 
parasites through the movement of infected individuals or, occasionally, 
infected anopheline vectors. Infectivity, or vector susceptibility, depends on 
the compatibility between the anopheline vector and the infecting strain of 
Plasmodium. 
National malaria programmes should undertake stratification by 
malariogenic potential in order to: differentiate receptive from non-
receptive areas; identify receptive areas in which malaria transmission has 
already been curtailed by current interventions; distinguish between areas 
with widespread transmission and those in which transmission occurs only 
in discrete foci; and determine geographical variations and population 
characteristics that are associated with vulnerability (25). 
Specific packages of interventions may be designed for implementation in 
the various strata identified. These may include:
• enhancement and optimization of vector control; 
• further strengthening of timely detection, high-quality diagnosis 
(confirmation), and management and tracking of cases;
• strategies to accelerate clearance of parasites or vectors in order to 
reduce transmission rapidly when possible;
• information, detection and response systems to identify, investigate 
and clear remaining malaria foci.
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In areas10 with ongoing local malaria transmission (irrespective of both the 
pre-intervention and the current level of transmission), the scale-back of 
vector control should not be undertaken. Universal coverage with effective 
malaria vector control of all persons in such areas should be pursued and 
maintained.
Good practice statement
In areas where transmission has been interrupted, the scale-back of vector 
control should be based on a detailed analysis that includes assessment 
of the receptivity and vulnerability, active disease surveillance system, and 
capacity for case management and vector control response.
Good practice statement
Access to effective vector control interventions will need to be maintained 
in the majority of countries and locations where malaria control has 
been effective. This includes settings with ongoing malaria transmission, 
as well as those in which transmission has been interrupted but in which 
some level of receptivity and vulnerability remains. Malaria elimination 
is defined as the interruption of local transmission (reduction to zero 
incidence of indigenous cases) of a specified malaria parasite species in a 
defined geographical area as a result of deliberate intervention activities. 
Following elimination, continued measures to prevent re-establishment of 
transmission are usually required (24). Interventions are no longer required 
once eradication has been achieved. Malaria eradication is defined as 
the permanent reduction to zero of the worldwide incidence of infection 
caused by all human malaria parasite species as a result of deliberate 
activities.
A comprehensive review of historical evidence and mathematical 
simulation modelling undertaken for WHO in 2015 indicated that the scale-
back of malaria vector control was associated with a high probability of 
malaria resurgence, including for most scenarios in areas where malaria 
transmission was very low or had been interrupted. Both the historical 
review and the simulation modelling clearly indicated that the risk of 
resurgence was significantly greater at higher EIRs and case importation 
rates, and lower coverage of active case detection and case management 
(26).
10 The minimum size of an area is determined by the availability of reliable disaggregated disease 
surveillance data and feasibility for decisions on vector control implementation. The area is not necessarily 
based on administrative boundaries.
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During the pre-elimination and elimination phases, ensuring universal 
access to vector control for at-risk populations remains a priority, even 
though the size and specific identity of the at-risk populations may change 
as malaria transmission is reduced. 
As malaria incidence falls and elimination is approached, increasing 
heterogeneity in transmission will result in foci with ongoing transmission 
in which vector control should be enhanced. Such foci may be due to 
particularly intense vectorial capacity, lapsed prevention and treatment 
services, changes in vectors or parasites that make the current strategies 
less effective, or reintroduction of malaria parasites by the movement 
of infected people or, more rarely, infected mosquitoes. Guidance 
on entomological surveillance across the continuum from control to 
elimination is provided elsewhere (23).
Once elimination has been achieved, vector control may need to 
be continued by targeting defined at-risk populations to prevent 
reintroduction or resumption of local transmission.
It is acknowledged that malaria transmission can persist following the 
implementation of a widely effective malaria programme. The sources and 
risks of ‘residual transmission’ may vary by location, time and the existing 
components of the current ‘effective malaria programme’. This variation is 
potentially due to a combination of both mosquito and human behaviours, 
such as when people live in or visit forest areas or do not sleep in protected 
houses, or when local mosquito vector species bite and/or rest outdoors 
and thereby avoid contact with IRS or ITN/LLIN. 
Supplementary interventions such as larval source management (LSM) 
can be used in addition to the core interventions in specific settings 
and circumstances. Recommendations on larviciding with chemical or 
biological insecticides are outlined in a subsequent chapter. The VCAG 
on new tools, technologies and approaches is currently evaluating a 
number of new interventions that have the potential to address residual 
transmission (http://www.who.int/vector-control/vcag/). Implementation 
of supplementary interventions should be in accordance with the principles 
outlined in the Global vector control response 2017–2030 (6). 
Once elimination has been achieved, vector control coverage should 
be maintained in receptive areas where there is a substantial risk for 
reintroduction (i.e. vulnerable areas). 
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SUPPLEMENTARY INTERVENTIONS
Once high coverage with a core intervention has been achieved, 
recommended supplementary interventions with proven public health 
value may be deployed as a public health intervention in specific settings 
and circumstances. The decision to deploy a supplementary vector control 
intervention should only be taken after conducting a prioritization analysis 
across malaria interventions, not just vector control, to ensure maximum 
impact of any additional resources.
Good practice statement
There is a critical need for all countries with ongoing malaria transmission, 
and in particular those approaching elimination, to build and maintain 
strong capacity in disease and entomological surveillance and health 
systems. The capacity to detect and respond to possible resurgences with 
appropriate vector control relies on having the necessary entomological 
information (i.e. susceptibility status of vectors to insecticides, as well as 
their biting and resting preferences). Such capacity is also required for the 
detailed assessment of malariogenic potential that is a pre-condition for 
determining whether vector control can be scaled back (or focalized). 
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4. Recommendations on 
core interventions
4.1 INSECTICIDE-TREATED NETS (ITNS)
WHO recommends ITNs – which in many settings should be LLINs – as 
a core intervention for use in protecting populations at risk of malaria, 
including in areas where malaria has been eliminated or transmission 
interrupted but the risk of reintroduction remains. An ITN repels, disables or 
kills mosquitoes that come into contact with the insecticide on the netting 
material. ITNs can produce a ‘community effect’ whereby even members 
of the community who do not sleep under a net gain some protection 
due to the effect of the treated nets on mosquito longevity (and therefore 
vectorial capacity). Large-scale field trials (27, 28) and transmission models 
(29, 30) suggest that absolute coverage of ≥50% of effectively treated 
nets is expected to result in community-wide protection of non-users in 
most settings and that, within these, further gains are realized as coverage 
increases. A community effect of ITNs has, however, not been observed 
in all settings (31, 32). WHO GMP has initiated a systematic review of the 
evidence base on the ‘community effect’ of ITNs to further investigate 
observed presence/absence of this effect depending on contextual factors 
and study designs, as well as the relationship between coverage and 
community-level impact in different transmission settings where this effect 
has been observed.  
Two main ITN classes are currently covered by a WHO policy 
recommendation:
• Pyrethroid-only nets, including LLINs: This product class covers both 
conventionally treated nets that rely on periodic re-treatment of 
nets by dipping into an insecticide formulation, and factory-treated 
LLINs made of netting material with insecticide incorporated within 
or bound around the fibres. LLINs are defined as retaining their 
effective biological activity for at least 20 WHO standard washes under 
laboratory conditions and three years of recommended use under field 
conditions.
• Pyrethroid-PBO net: This product class contains both a pyrethroid 
insecticide and the synergist piperonyl butoxide (PBO). 
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ITNs are most effective where the principal malaria vector(s) mosquitoes 
bite predominantly at night after people have retired under their nets. ITNs 
can be used both indoors and outdoors, wherever they can be suitably 
hung (though hanging nets in direct sunlight should be avoided, as sunlight 
can affect insecticidal activity). 
Pyrethroid-only nets
PYRETHROID-ONLY NETS
Pyrethroid-only LLINs prequalified by WHO are recommended for 
deployment as a core intervention in all malaria-endemic settings.
Strong recommendation as a public health intervention, high-certainty 
evidence
BOX 3
Summary of evidence from Cochrane systematic review
Of the 23 included studies, 21 were cluster RCTs (six with households 
as the cluster and 15 with villages as the cluster) and two were 
individual RCTs; 12 studies compared ITNs with untreated nets, and 
11 studies compared ITNs with no nets. Based on WHO regions, 
12 studies were conducted in  Africa (Burkina Faso, Cote d’Ivoire, 
Cameroon, Gambia (two studies), Ghana, Kenya (three studies), 
Madagascar, Sierra Leone, United Republic of Tanzania), six in the 
Americas (Colombia, Ecuador, Nicaragua (two studies), Peru and 
Venezuela) and four in South-East Asia (India, Myanmar, Thailand 
(two studies)) and one in the Eastern Mediterranean (Pakistan).
ITNs versus no ITNs:
• ITNs reduce the rate of all-cause child mortality compared to no 
nets
(Rate Ratio: 0.83; 95% CI (0.77–0.89); five studies; high certainty evidence)
• ITNs reduce the rate of uncomplicated episodes of P. falciparum 
compared to no nets
(Rate Ratio: 0.54; 95% CI (0.48–0.60); five studies; high certainty 
evidence)
• ITNs reduce the prevalence of P. falciparum infection compared to 
no nets
(Rate Ratio: 0.69; 95% CI (0.54–0.89); five studies; high certainty evidence)
36
• ITNs may have little or no effect on the prevalence of P. vivax 
infection compared to no nets
(Risk Ratio: 1.00; 95% CI (0.75–1.34); two studies; low certainty evidence)
• ITNs reduce the incidence rate of severe malaria episodes 
compared to no nets
(Rate Ratio: 0.56; 95% CI (0.38–0.82); two studies; high certainty evidence)
ITNs versus untreated nets:
• ITNs probably reduce the rate of all-cause child mortality 
compared to untreated nets
(Rate Ratio: 0.67; 95% CI (0.36–1.23); two studies; moderate certainty 
evidence)
• ITNs reduce the rate of uncomplicated episodes of P. falciparum 
compared to untreated nets
(Rate Ratio: 0.58; 95% CI (0.43–0.79); five studies; high certainty evidence)
• ITNs reduce the prevalence of P. falciparum compared to 
untreated nets
(Risk Ratio: 0.81; 95% CI (0.68–0.97); four studies; high certainty evidence)
• ITNs may reduce the rate of uncomplicated episodes of P. vivax 
compared to untreated nets
(Rate Ratio: 0.73; 95% CI (0.51–1.05); three studies; low certainty evidence)
• The effect of ITNs on the prevalence of P. vivax, compared to 
untreated nets, is unknown
(Risk Ratio: 0.52; 95% CI (0.13–2.04); two studies; very low certainty 
evidence)
The Cochrane systematic review produced high certainty evidence that, 
compared to no nets, ITNs are effective in reducing the rate of all-cause 
child mortality, the rate of uncomplicated episodes of P. falciparum, the 
incidence rate of severe malaria episodes, and the prevalence of   
P. falciparum. ITNs may also reduce the prevalence of P. vivax, but here the 
evidence of an effect is less certain.
Compared to untreated nets, there is high certainty evidence that ITNs 
reduce the rate of uncomplicated episodes of P. falciparum and reduce 
the prevalence of P. falciparum. There is moderate certainty evidence that 
ITNs also reduce all-cause child mortality compared to untreated nets. The 
effects on the incidence of uncomplicated P. vivax episodes and P. vivax 
prevalence are less clear. 
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The systematic review did not identify any undesirable effects of pyrethroid 
ITNs. 
The current WHO policy recommendation for ITNs applies only to those 
mosquito nets that have a current WHO PQ listing and that contain only an 
insecticide of the pyrethroid class11 (categorized as ‘pyrethroid-only LLINs’) 
(3). For ITNs that currently do not have a policy recommendation, including 
nets treated with another class of insecticide either alone or in addition 
to a pyrethroid insecticide, WHO will determine the data requirements 
for assessing their public health value based on technical advice from the 
VCAG. In 2017, a separate recommendation applicable to pyrethroid nets 
treated with a synergist (‘pyrethroid-PBO nets’) was formulated based on 
the latest available evidence (33). 
Pyrethroid-PBO nets
PYRETHROID-PBO NETS
Pyrethroid-PBO nets prequalified by WHO are conditionally recommended 
for deployment instead of pyrethroid-only LLINs where the principal 
malaria vector(s) exhibit pyrethroid resistance that is: a) confirmed, 
b) of intermediate level,12 and c) conferred (at least in part) by a 
monooxygenase-based resistance mechanism, as determined by standard 
procedures.
Conditional recommendation as a public health intervention, moderate-
certainty evidence
Mosquito nets that include both a pyrethroid insecticide and the synergist 
PBO have become available. PBO acts by inhibiting certain metabolic 
enzymes (e.g. mixed-function oxidases) within the mosquito that detoxify or 
sequester insecticides before they can have a toxic effect on the mosquito. 
Therefore, compared to a pyrethroid-only net, a pyrethroid-PBO net 
should, in theory, have an increased killing effect on malaria vectors that 
express such resistance mechanisms. However, the entomological and 
epidemiological impact of pyrethroid-PBO nets may vary depending on 
the bioavailability and retention of PBO in the net, and on the design of the 
net (i.e. whether only some or all panels are treated with PBO). At present it 
is unknown how these differences in the design/composition of pyrethroid-
11 As per the Insecticide Resistance Action Committee Mode of Action Classification Scheme, available on 
the IRAC website: www.irac-online.org
12 Defined as 10–80% mortality in standard WHO susceptibility tests or CDC bottle bioassays
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PBO nets affect their relative efficacy. A non-inferiority design for 
experimental hut studies with entomological endpoints is being explored by 
WHO as a means to provide clarity in this respect.
Epidemiological data from one cluster RCT indicated that a pyrethroid-
PBO net product had additional public health value compared to a 
pyrethroid-only LLIN product in an area where the principal malaria 
vector(s) had confirmed pyrethroid resistance of moderate intensity 
conferred (at least in part) by monooxygenase-based resistance 
mechanism, as determined by standard procedures. On the basis of the 
current evidence, WHO has concluded and recommended the following:  
1. Based on the epidemiological findings and the need to deploy 
products that are effective against pyrethroid-resistant mosquitoes, 
pyrethroid-PBO nets are being given a conditional endorsement as a 
new WHO class of vector control products. 
2. National malaria control programmes and their partners should 
consider the deployment of pyrethroid-PBO nets in areas where 
the principal malaria vector(s) have pyrethroid resistance that is: 
a) confirmed, b) of intermediate level (as defined above), and  
c) conferred (at least in part) by a monooxygenase-based resistance 
mechanism, as determined by standard procedures. Deployment 
of pyrethroid-PBO nets must only be considered in situations where 
coverage with effective vector control (primarily LLINs or IRS) will 
not be reduced; the primary goal must remain the achievement and 
maintenance of universal coverage for all people at risk of malaria. 
3. Further evidence on pyrethroid-PBO nets is required to support 
the refinement of WHO guidance regarding the conditions for the 
deployment of products in this class.
4. Pyrethroid-PBO nets should not be considered a tool that can alone 
effectively manage insecticide resistance in malaria vectors. It is an 
urgent task to develop and evaluate ITNs treated with non-pyrethroid 
insecticides and other innovative vector control interventions for 
deployment across all settings, in order to provide alternatives for use 
in a comprehensive IRM strategy.
Further details are available in the full document online (32). The 
conditional recommendation will be updated based on a systematic 
review published in late 2018 (https://www.cochranelibrary.com/cdsr/
doi/10.1002/14651858.CD012776.pub2/full), once data from an ongoing 
second study with epidemiological outcomes have been assessed by the 
VCAG.
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Achieving and maintaining universal coverage with ITNs for 
malaria prevention and control
Recipients of ITNs should be advised (through appropriate communication 
strategies) to continue using their nets beyond the three-year anticipated 
lifespan of the net, irrespective of the condition of the net, until a 
replacement net is available.
Good practice statement
Recipients of ITNs should be advised (through appropriate communication 
strategies) to continue using their net even if it is damaged or contains 
holes, irrespective of the age of the net, until a replacement net is available.
Good practice statement
In December 2017, WHO published updated recommendations on 
achieving and maintaining universal coverage with LLINs (34). These 
recommendations were developed and revised based on expert opinion 
through broad consultation, including multiple rounds of reviews by the 
MPAC. Below, these recommendations have been summarized and slightly 
revised to clarify that these recommendations are not specific to LLINs, but 
apply to ITNs in general. 
To achieve and maintain universal ITN coverage, countries should 
apply a combination of mass free net distribution through campaigns 
and continuous distribution through multiple channels, in particular 
through antenatal care (ANC) clinics and the Expanded Programme on 
Immunization (EPI). Mass campaigns are the only proven cost-effective 
way to rapidly achieve high and equitable coverage. Complementary 
continuous distribution channels are also required because coverage 
gaps can start to appear almost immediately post-campaign due to net 
deterioration, loss of nets, and population growth.
Mass campaigns should distribute 1 ITN for every 2 persons at risk of 
malaria. However, for procurement purposes, the calculation to determine 
the number of ITNs required needs to be adjusted at the population level, 
since many households have an odd number of members. Therefore 
a ratio of 1 ITN for every 1.8 persons in the target population should be 
used to estimate ITN requirements, unless data to inform a different 
quantification ratio are available. In places where the most recent 
population census is more than five years old, countries can consider 
including a buffer (e.g. adding 10% after the 1.8 ratio has been applied) 
or using data from previous ITN campaigns to justify an alternative buffer 
amount. Campaigns should also normally be repeated every three years, 
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unless available empirical evidence justifies the use of a longer or shorter 
interval between campaigns. In addition to these data-driven decisions, 
a shorter distribution interval may also be justified during humanitarian 
emergencies, as the resulting increase in population movement may leave 
populations uncovered by vector control and potentially increase their risk 
of infection as well as the risk of epidemics.
Continuous distribution through ANC and EPI channels should remain 
functional before, during and after mass distribution campaigns. School-
based distribution should be discontinued in campaign years to avoid 
over-supply of ITNs. In areas where school-based distributions are 
operating at scale and achieve high coverage, these distributions may 
even be sufficient to replace mass distribution campaigns.
‘Top-up’ campaigns (i.e. ITN distributions that take into account existing 
nets in households and provide each household only with the additional 
number of nets needed to bring it up to the target number) are not 
recommended. Substantial field experience has shown that accurate 
quantification for such campaigns is generally not feasible and the cost of 
accounting for existing nets outweighs the benefits.
There should be a single national ITN plan and policy that includes both 
continuous and campaign distribution strategies. This should be developed 
and implemented under the leadership of the national malaria control 
programme, and based on analysis of local opportunities and constraints, 
and identification of a combination of distribution channels with which to 
achieve universal coverage and minimize gaps. This unified plan should 
include a comprehensive net quantification and gap analysis for all public 
sector ITN distribution channels. As much as possible, the plan should also 
include major ITN contributions by the private sector.
Therefore, in addition to mass campaigns, the distribution strategy could 
include: 
• ANC, EPI and other child health clinics: These should be considered 
high-priority continuous ITN distribution channels in countries where 
these services are used by a large proportion of the population at risk 
of malaria, as occurs in much of sub-Saharan Africa.
• Schools, faith- and community-based networks, and agricultural 
and food-security support schemes: These can also be explored 
as channels for ITN distribution in countries where such approaches 
are feasible and equitable. Investigating the potential use of these 
distribution channels in complex emergencies is particularly important.
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• Occupation-related distribution channels: In some settings, particularly 
in Asia, the risk of malaria may be strongly associated with specific 
occupations (e.g. plantation and farm workers and their families, 
miners, soldiers and forest workers). In these settings, opportunities 
for distribution through channels such as private sector employers, 
workplace programmes and farmers’ organizations may be explored.
• Private or commercial sector channels: These can be important 
channels for supplementing free ITN distribution through public sector 
channels. Access to ITNs can also be expanded by facilitating the 
exchange of vouchers or coupons provided through public sector 
channels for a free or subsidized ITN at participating retail outlets. ITN 
products distributed through the private sector should be regulated 
by the national registrar of pesticides in order to ensure that product 
quality is in line with WHO recommendations.
The procurement of ITNs with attributes that are more costly (e.g. nets of 
conical shape) is not recommended for countries in sub-Saharan Africa, 
unless nationally representative data clearly show that the use of ITNs with 
particular attributes increases significantly among populations at risk of 
malaria. To build an evidence base to support the purchase of more costly 
nets, investigation into the preferences of specific population groups at risk 
of malaria may also be warranted if standard nets are unlikely to suit the 
lifestyle of these groups, such as may be the case for nomadic populations.
The lifespans of ITNs can vary widely among individual nets used 
within a single household or community, as well as among nets used 
in different settings. This makes it difficult to plan the rate or frequency 
at which replacement nets need to be procured and delivered. All 
malaria programmes that have undertaken medium- to large-scale 
ITN distributions should conduct ITN durability monitoring in line with 
available guidance to inform appropriate replacement intervals. 
Where there is evidence that ITNs are not being adequately cared for 
or used, programmes should design and implement behaviour change 
communication activities aimed at improving these behaviours.
In countries where untreated nets are widely available, national malaria 
control programmes should promote access to ITNs. Strategies for treating 
untreated nets can also be considered, for example, by supporting access 
to insecticide treatment kits.
As national malaria control programmes implement different mixes 
of distribution methods, there will be a need to accurately track ITN 
coverage at the district level. Subnational responses should be triggered if 
coverage falls below programmatic targets. Tracking must differentiate the 
contributions of various delivery channels to overall ITN coverage.
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Countries should generate data on defined standard indicators of 
coverage and access rates in order to ascertain whether universal 
coverage has been achieved and maintained. The data should also inform 
changes in implementation in order to improve performance and progress 
towards the achievement of programmatic targets. Currently, the three 
basic survey indicators are: i) the proportion of households with at least one 
ITN; ii) the proportion of the population with access to an ITN within their 
household; and iii) the proportion of the population reporting having slept 
under an ITN the previous night (by age (<5 years; 5–14 years; 15+ years), 
gender and access to ITN).
Management of old ITNs
COLLECTION AND DISPOSAL OF OLD ITNS
Old ITNs should only be collected where there is assurance that: 
i) communities are not left uncovered, i.e. new ITNs are distributed to 
replace old ones; and ii) there is a suitable and sustainable plan in place 
for safe disposal of the collected material.
Good practice statement
If ITNs and their packaging (bags and baling materials) are collected, 
the best option for disposal is high-temperature incineration. They should 
not be burned in the open air. In the absence of appropriate facilities, 
they should be buried away from water sources and preferably in non-
permeable soil.
Good practice statement
Recipients of ITNs should be advised (through appropriate communication 
strategies) not to dispose of their nets in any water body, as the residual 
insecticide on the net can be toxic to aquatic organisms (especially fish).
Strong recommendation, high-certainty evidence
Currently, LLINs and the vast majority of their packaging (bags and baling 
materials) are made of non-biodegradable plastics (35). The large-scale 
deployment of LLINs has given rise to questions as to the most appropriate 
and cost-effective way to deal with the resulting plastic waste, particularly 
given that most endemic countries currently do not have the resources to 
manage LLIN collection and waste disposal programmes. 
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A pilot study was conducted to examine patterns of LLIN usage and 
disposal in three African countries (Kenya, Madagascar and United 
Republic of Tanzania). Findings of this pilot study along with other 
background information were used to generate recommendations through 
the WHO VCTEG and MPAC on best practices with respect to managing 
LLIN waste. 
The following are the main findings from the pilot study and other 
background material: 
1. LLINs entering domestic use in Africa each year contribute 
approximately 100 000 tonnes of plastic and represent a per capita 
rate of plastic consumption of 200 grams per year. This is substantial 
in absolute terms, but constitutes only approximately 1% to 5% of the 
total plastic consumption in Africa and thus is small compared to other 
sources of plastic and other forms of plastic consumption.
2. The plastic from LLINs is treated with a small amount of pyrethroid 
insecticide (less than 1% per unit mass for most products), and plastic 
packaging is therefore considered a pesticide product/container.
3. Old LLINs and other nets may be used for a variety of alternative 
purposes, usually due to perceived ineffectiveness of the net, loss of net 
physical integrity or presence of another net.
4. LLINs that no longer serve a purpose are generally disposed of at the 
community level along with other household waste by either discarding 
them in the environment, burning them in the open, or placing them 
into pits.
5. LLIN collection was not implemented on a large scale or sustained in 
any of the pilot study countries. It may be feasible to recycle LLINs, but 
it is not practical or cost-effective at this point, as there would need to 
be specialized adaptation and upgrading of recycling facilities before 
insecticide-contaminated materials could be included in this process.
6. Two important and potentially hazardous practices are: i) routinely 
removing LLINs from bags at the point of distribution and burning 
discarded bags and old LLINs, which can produce highly toxic fumes 
including dioxins, and ii) discarding old LLINs and their packaging in 
water, as they may contain high concentrations of residual insecticides 
that are toxic to aquatic organisms, particularly fish.
7. Insecticide-treated plastics can be incinerated safely in high-
temperature furnaces, but suitable facilities are lacking in most 
countries. Burial away from water sources and preferably in non-
permeable soil is an appropriate method to dispose of net bags and 
old LLINs in the absence of a suitable high-temperature incinerator.
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8. In most countries, ministries of environment (national environment 
management authorities) are responsible for setting up and enforcing 
laws/regulations to manage plastic waste broadly. Although some 
countries have established procedures for dealing with pesticide-
contaminated plastics, it is unrealistic to expect national malaria control 
and elimination programmes to single-handedly address the problem 
of managing waste from LLINs. Environmental regulations; leadership 
and guidance from national environmental authorities; and oversight 
from international agencies, such as the United Nations Environment 
Programme, are all necessary. 
It is important to determine whether the environmental benefits outweigh 
the costs when identifying the best disposal option for old LLINs and their 
packaging. For malaria programmes in most endemic countries, there are 
limited options for dealing with the collection. Recycling is not currently a 
practical option in most malaria-endemic countries (with some exceptions 
for countries with a well-developed plastics industry). High-temperature 
incineration is likely to be logistically difficult and expensive in most 
settings. In practice, when malaria programmes have retained or collected 
packaging material in the process of distributing LLINs, it has mostly been 
burned in the open air. This method of disposal may lead to the release of 
dioxins, which are harmful to human health. 
If such plastic material (with packaging an issue at the point of distribution 
and old LLINs an intermittent issue at household level when the net is no 
longer in use) is left in the community, it is likely to be re-used in a variety 
of ways. While the insecticide-exposure entailed by this kind of re-use has 
not yet been fully studied, the expected negative health and environmental 
impacts of leaving it in the community are considered less than amassing 
the waste in one location and/or burning it in the open air.
Since the material from nets represents only a small proportion of total 
plastic consumption, it will often be more efficient for old LLINs to be dealt 
with as part of larger and more general solid-waste programmes. National 
environment management authorities have an obligation to consider 
and plan for what happens to old LLINs and packing materials in the 
environment in collaboration with other relevant partners. 
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4.2 INDOOR RESIDUAL SPRAYING (IRS)
IRS is the application of a residual insecticide to potential malaria vector 
resting surfaces, such as internal walls, eaves and ceilings of houses or 
structures (including domestic animal shelters), where such vectors might 
come into contact with the insecticide. IRS with a product that has a 
WHO PQ listing is a core intervention for deployment in malaria-endemic 
locations. DDT, which has not been prequalified, may be used for IRS if no 
equally effective and efficient alternative is available, and if it is used in line 
with the Stockholm Convention on Persistent Organic Pollutants.
INDOOR RESIDUAL SPRAYING
IRS deploying a product prequalified by WHO is recommended as a 
core intervention in all malaria-endemic settings. DDT has not been 
prequalified; it may be used for IRS if no equally effective and efficient 
alternative is available, and if it is used in line with the Stockholm 
Convention on Persistent Organic Pollutants.
Strong recommendation as a public health intervention, low-certainty evidence
IRS versus no IRS in areas with unstable transmission:
• IRS may reduce malaria incidence compared to no IRS
(Risk Ratio: 0.12; 95% CI (0.04–0.31); one study; low certainty evidence)
• IRS may reduce parasite prevalence compared to no IRS
(Risk Ratio: 0.24; 95% CI (0.17–0.34); one study; low certainty evidence)
IRS versus ITNs in areas with intense transmission:
• IRS may reduce malaria incidence compared to ITNs
(Rate Ratio: 0.88; 95% CI (0.78–0.98); one study; low certainty evidence)
• There may be little or no difference between IRS and ITNs in terms 
of parasite prevalence
(Risk Ratio: 1.06; 95% CI (0.91–1.22); one study; very low certainty evidence)
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When carried out correctly, IRS has historically been shown to be a 
powerful intervention to reduce adult mosquito vector density and 
longevity and, therefore, to reduce malaria transmission. However, few 
RCTs have been conducted on IRS and so the availability of data suitable 
for use in a Cochrane-style meta-analysis is limited. The Guidelines 
Development Group determined that the data from these randomized 
trials, as well as the large body of evidence generated from other studies, 
warranted the continued recommendation of IRS as a core intervention 
for malaria prevention and control. A systematic review of evidence 
from non-randomized studies will be undertaken to further underpin this 
recommendation or modify it as appropriate. 
Insecticide formulations for IRS (1) fall into five major insecticide classes 
with three modes of action,13 based on their primary target site in the 
vector:
Sodium channel modulators
• Pyrethroids: alphacypermethrin, deltamethrin, lambda-cyhalothrin, 
etofenprox, bifenthrin, cyfluthrin  
• Organochlorines: DDT 
Acetylcholinesterase inhibitors
• Organophosphates: malathion, fenitrothion, pirimiphos-methyl 
• Carbamates: bendiocarb, propoxur  
Nicotinic acetylcholine receptor competitive modulators
• Neonicotinoids: clothianidin
13 As per the Insecticide Resistance Action Committee Mode of Action Classification Scheme, available on 
the IRAC website: www.irac-online.org
IRS versus ITNs in areas with unstable transmission:
• IRS may increase malaria incidence compared to ITNs
(Rate Ratio: 1.48; 95% CI (1.37–1.60); one study; low certainty evidence)
• IRS may increase parasite prevalence compared to ITNs
(Risk Ratio: 1.70; 95% CI (1.18–2.44); one study; low certainty evidence)
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IRS products using four of these insecticide classes have been pre-
qualified by WHO; as of February 2019, there were no DDT IRS formulations 
prequalified. The products listed have been prequalified based on their 
safety, quality and entomoligical efficacy, which includes evaluation of their 
mortality effect on mosquitoes when applied to a range of interior surfaces 
of dwellings found in malaria-endemic areas. Residual efficacy needs to 
continue for at least three months after the application of the insecticide to 
the substrate, usually cement, mud or wood (36). Insecticides are available 
in various formulations to increase their longevity on different surfaces.
IRS is considered an appropriate intervention where:
• the majority of the vector population feeds and rests inside houses;
• the vectors are susceptible to the insecticide that is being deployed;
• people mainly sleep indoors at night;
• the malaria transmission pattern is such that the population can be 
protected by one or two rounds of IRS per year;
• the majority of structures are suitable for spraying; and
• structures are not scattered over a wide area, resulting in high 
transportation and other logistical costs.
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5. Recommendations 
on supplementary 
interventions
5.1 LARVAL SOURCE MANAGEMENT (LSM)
LSM is the management of aquatic habitats (water bodies) that are 
potential larval habitats for mosquitoes in order to prevent the completion 
of development of the immature stages (eggs, larvae and pupae) and 
hence the production of adult mosquitoes. There are four types of LSM:
• habitat modification: a permanent alteration to the environment, 
e.g. land reclamation;
• habitat manipulation: a recurrent activity, e.g. flushing of streams;
• larviciding: the regular application of biological or chemical 
insecticides to water bodies;
• biological control: the introduction of natural predators into water 
bodies.
In general, environmental management (habitat modification and 
manipulation) should, where feasible, be the primary strategy to reduce 
the availability of larval habitats. However, no systematic reviews have so 
far been conducted to inform the development of WHO guidance in this 
area, and the Guidelines Development Group therefore did not consider 
habitat modification and manipulation in developing the 1st edition of the 
Guidelines. Independent systematic reviews of the available evidence on 
these interventions will be conducted to inform the inclusion of guidance as 
part of revision to the Guidelines.
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LARVICIDING
The regular application of biological or chemical insecticides to water 
bodies (larviciding) is recommended for malaria prevention and control 
as a supplementary intervention in areas where high coverage with a core 
intervention has been achieved, where aquatic habitats are few, fixed and 
findable, and where its application is both feasible and cost-effective.
Conditional recommendation as a public health intervention, low-certainty 
evidence
BOX 5 
Summary of evidence from Cochrane systematic review
Larviciding versus no larviciding:
Four studies were included in the systematic review, of which only 
one was an RCT; the remaining three studies were non-randomized. 
Studies were undertaken in Gambia, Kenya, Sri Lanka and United 
Republic of Tanzania.   
Larviciding applied to mosquito aquatic habitats exceeding 1km2 
in area:
• It is unknown whether larviciding has an effect on malaria 
incidence compared to no larviciding
(Odds Ratio: 1.97; 95% CI (1.39–2.81); one study; very low certainty 
evidence)
• It is unknown whether larviciding has an effect on parasite 
prevalence compared to no larviciding
(Odds Ratio: 1.49; 95% CI (0.45–4.93); one study; very low certainty 
evidence) 
Larviciding applied to mosquito aquatic habitats less than 1km2 in 
area:
• Larviciding probably reduces malaria incidence compared to no 
larviciding
(Rate Ratio: 0.20; 95% CI (0.16–0.25); one study; moderate certainty 
evidence)
• Larviciding may reduce parasite prevalence compared to no 
larviciding
(Odds Ratio: 0.72; 95% CI (0.58–0.89); two studies; low certainty evidence)
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Since larviciding only reduces vector density, it does not have the same 
potential for health impact as ITNs and IRS – both of which reduce 
vector longevity (a key determinant of transmission intensity) and provide 
protection from biting vectors. As a result, larviciding should never be 
seen as a substitute for ITNs or IRS in areas with significant malaria risk. 
Larviciding is most likely to be cost-effective in urban areas where the 
appropriate conditions are more likely to be present. Larviciding is not 
generally recommended in rural settings, unless there are particular 
circumstances limiting the larval habitats and specific evidence confirming 
that such measures can reduce malaria incidence in the local setting. 
The WHO 2013 operational manual on LSM (37) concludes that LLINs and 
IRS remain the backbone of malaria vector control, but LSM represents 
an additional (supplementary) strategy for malaria control in Africa. 
Larviciding will generally be most effective in areas where larval habitats 
are few, fixed and findable, and likely less feasible in areas where the 
aquatic habitats are abundant, scattered and variable. Determination 
of whether or not specific habitats are suitable for larviciding should be 
based on assessment by an entomologist. The WHO operational manual 
focuses on sub-Saharan Africa, but the principles espoused are likely to 
hold for other geographic regions that fit the same criteria. The following 
settings are potentially the most suitable for larviciding as a supplementary 
measure implemented alongside the core interventions:
• urban areas: where breeding sites are relatively few, fixed and 
findable in relation to houses (which are targeted for ITNs or IRS);
• arid regions: where larval habitats may be few and fixed throughout 
much of the year.
LARVIVOROUS FISH
No recommendation can be made because evidence on the effectiveness 
(or harms) of larvivorous fish was not identified.
No recommendation, insufficient evidence
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BOX 6
Summary of evidence from Cochrane systematic review
Larvivorous fish versus no larvivorous fish:
Fifteen studies were included in the systematic review. Studies were 
undertaken in Comoros, Ethiopia, India (three studies), Indonesia, 
Kenya, Republic of Korea (two studies), Sri Lanka (two studies), 
Sudan, and Tajikistan (two studies). 
Treated aquatic habitats included wells, domestic water containers, 
fishponds and pools (seven studies); river bed pools below dams 
(two studies); rice field plots (four studies); and canals (two studies).
No studies reported on clinical malaria, EIR or adult vector densities; 
12 studies reported on density of immature stages; and five studies 
reported on the number of aquatic habitats positive for immature 
stages of the vector species.
The studies were not suitable for a pooled analysis.
• It is unknown whether larvivorous fish reduce the density of 
immature vector stages compared to no larvivorous fish
(unpooled data; 12 studies; very low certainty evidence)
• Larvivorous fish may reduce the number of larval sites positive for 
immature vector stages compared to no larvivorous fish
(unpooled data; five studies; low certainty evidence)
No recommendation can be made at the present time on the deployment 
of larvivorous fish as a malaria prevention and control intervention 
because evidence on the effectiveness (or potential harm) of larvivorous 
fish was not identified during the systematic review.
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6. Recommendations 
on personal protection 
measures
6.1 TOPICAL REPELLENTS, INSECTICIDE-TREATED 
CLOTHING AND SPATIAL/AIRBORNE REPELLENTS
Topical repellents, insecticide-treated clothing and spatial/airborne 
repellents have all been proposed as potential methods for malaria 
prevention in areas where the mosquito vectors bite or rest outdoors, or 
bite in the early evening or early morning when people are not within 
housing structures. They have also been proposed for specific population 
groups, such as those who live or work away from permanent housing 
structures (e.g. migrants, refugees, internally displaced persons, military 
personnel) or those who work outdoors at night. In these situations, the 
effectiveness of the core interventions (ITNs or IRS) may be reduced. 
Repellents have also been proposed for use in high-risk groups, such as 
pregnant mothers. Despite the potential to provide individual protection 
against bites from malaria vectors, the deployment of the above personal 
protective methods in large-scale public health campaigns has been 
limited, at least partially due to the scarcity of evidence of their public 
health value. Daily compliance and appropriate use of the repellents seem 
to be major obstacles to achieving such potential impact (38). Individuals’ 
use of the intervention to achieve personal protection faces the same 
obstacles.
TOPICAL REPELLENTS
Deployment of topical repellents for malaria prevention is not 
recommended as an intervention with public health value; however, 
topical repellents may be beneficial as an intervention to provide personal 
protection against malaria.
Conditional recommendation against deployment as an intervention with 
public health value, low-certainty evidence
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BOX 7.
Summary of evidence from Cochrane systematic review
Topical repellent versus placebo or no topical repellent:
A total of six RCTs were included in the review. Studies were 
conducted among residents in Plurinational State of Bolivia, 
Cambodia, Lao People’s Democratic Republic and United Republic 
of Tanzania, and in specific populations in Pakistan (refugees) and 
Thailand (pregnant women). 
• It is unknown whether topical repellents have an effect on clinical 
malaria caused by P. falciparum 
(Risk Ratio: 0.65; 95% CI (0.40–1.07); three studies; very low certainty 
evidence)
• Topical repellents may or may not have a protective effect against  
P. falciparum parasitaemia
(Risk Ratio: 0.84; 95% CI (0.64–1.12); four studies; low certainty evidence)
• Topical repellents may increase the number of clinical cases 
caused by P. vivax
(Risk Ratio: 1.32; 95% CI (0.99–1.76); two studies; low certainty evidence)
• Topical repellents may or may not have a protective effect against 
P. vivax parasitaemia
(Risk Ratio: 1.07; 95% CI (0.80–1.41); three studies; low certainty evidence)
The evidence from the RCTs provides low certainty evidence of a possible 
effect of topical repellents on malaria parasitaemia (P. falciparum and  
P. vivax). The evidence is insufficiently robust to determine whether topical 
repellents have an effect on clinical malaria.
INSECTICIDE-TREATED CLOTHING
Deployment of insecticide-treated clothing for malaria prevention is 
not recommended as an intervention with public health value; however, 
insecticide-treated clothing may be beneficial as an intervention to provide 
personal protection against malaria in specific population groups. 
Conditional recommendation against deployment as an intervention with 
public health value, low-certainty evidence
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BOX 8.
Summary of evidence from Cochrane systematic review
Insecticide-treated clothing versus placebo or untreated clothing:
Two RCTs were included in the systematic review. Studies were 
conducted in specific populations in Colombia (military personnel) 
and Pakistan (Afghan refugees).
• Insecticide-treated clothing may have a protective effect against 
clinical malaria caused by P. falciparum
(Risk Ratio: 0.49; 95% CI (0.29–0.83); two studies; low certainty evidence)
• Insecticide-treated clothing may have a protective effect against 
clinical malaria caused by P. vivax
(Risk Ratio: 0.64; 95% CI (0.40–1.01); two studies; low certainty evidence)
There is low certainty evidence that insecticide-treated clothing may 
have protective efficacy against P. falciparum and P. vivax cases, at least 
in certain specific populations (refugees, military personnel and others 
engaged in occupations that place them at high risk).
SPATIAL/AIRBORNE REPELLENTS
No recommendation on the deployment of spatial/airborne repellents 
in the prevention and control of malaria can be made until more studies 
assessing malaria epidemiological outcomes have been conducted. 
No recommendation, very low-certainty evidence
BOX 9.
Summary of evidence from Cochrane systematic review
Spatial/airborne repellents versus placebo or no malaria 
prevention intervention:
Two RCTs were included in the systematic review. Studies were 
conducted in China and Indonesia.
• It is unknown whether spatial repellents protect against malaria 
parasitaemia
(Risk Ratio: 0.24; 95% CI (0.03–1.72); two studies; very low certainty 
evidence)
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There is very low certainty evidence that spatial or airborne repellents may 
have a protective efficacy against malaria parasitaemia. Therefore, no 
recommendation on the use of spatial/airborne repellents in the prevention 
and control of malaria can be made until more studies assessing malaria 
epidemiological outcomes have been conducted.
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7. Other interventions
7.1 SPACE SPRAYING
Space spraying refers to the release of fast-acting insecticides into the air 
as smoke or as fine droplets as a method to reduce the numbers of adult 
mosquitoes in dwellings and also outdoors. Application methods include 
thermal fogging; cold aerosol distribution by handheld or backpack 
sprayers, ground vehicles or aerial means; and repetitious spraying by two 
or more sprays in quick succession. It is most often deployed in response to 
epidemics or outbreaks of mosquito-borne disease, such as dengue. 
SPACE SPRAYING
Space spraying should not be undertaken for malaria control, and IRS or 
ITNs should be prioritized instead. 
Conditional recommendation against deployment, very low-certainty evidence 
BOX 10.
Summary of evidence from Cochrane systematic review
Space spraying versus no space spraying:
A total of three interrupted time series studies were included in the 
review. These studies were conducted in Haiti (malathion applied 
by aerial delivery) and India (malathion applied with handheld 
sprayers; malathion applied with handheld and vehicle-mounted 
sprayers). Two controlled before-and-after studies (one cluster per 
arm) were conducted in El Salvador (pyrethrin and PBO applied 
with vehicle-mounted sprayers) and Malaysia (alphacypermethrin 
applied with handheld sprayers).
All of the included studies were observational studies, which are 
initially categorized as yielding low certainty evidence. The risk of 
bias in the studies resulted in the certainty of evidence being further 
downgraded to very low.
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• It is unknown whether space spraying causes a reduction in 
incidence of malaria
(Step Rate Ratio: 1.03; 95% CI (0.58–1.82); five studies; very low certainty 
evidence)
(Slope Rate Ratio: 0.88; 95% CI (0.81–0.94); five studies; very low certainty 
evidence)
The reliance on observational studies and the lack of data from RCTs, 
other trial designs or quasi-experimental studies has hampered a 
comprehensive assessment of this intervention. Review of the evidence 
indicated that it is unknown whether space spraying causes a reduction 
in incidence of malaria. Nevertheless, space spraying is often deployed in 
response to outbreaks of mosquito-borne disease. Due to the high visibility 
of this intervention, the decision to use this approach is usually made 
to demonstrate that the authorities are taking action in response to the 
outbreak. This practice should be strongly discouraged given the limited 
evidence of the intervention’s effectiveness and the potential for wastage 
of resources. The Guidelines Development Group therefore felt it necessary 
to develop a clear recommendation against space spraying for malaria 
control. 
7.2 HOUSING IMPROVEMENTS
Available evidence indicates that poor-quality housing and neglected 
peridomestic environments are risk factors for the transmission of malaria, 
arboviral diseases (e.g. dengue, yellow fever, chikungunya, Zika virus 
disease), Chagas disease and leishmaniasis (39). Closing open eaves, 
screening doors and windows with fly screens or mosquito netting, and 
filling holes and cracks in walls and roofs reduce the mosquitoes’ entry 
points into houses. Together with metal roofs, ceilings, and finished interior 
walls, these modifications may reduce transmission of malaria and other 
vector-borne diseases.
A recent review indicated that housing quality is an important risk factor 
for malaria infection across the spectrum of malaria endemicity in sub-
Saharan Africa (40). However, specific evidence-based recommendations 
on housing and vector-borne diseases are still needed. To this end, the 
WHO Department of Public Health, Environmental and Social Determinants 
of Health is currently developing housing and health guidelines. To 
support the development of these guidelines, WHO has commissioned 
a systematic review of housing and vector-borne diseases by the CIDG. 
Once available, the outcomes of this review will be presented to the 
Guidelines Development Group with a view to formulating evidence-based 
recommendations for inclusion in both the housing and the malaria vector 
control guidelines.
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8. Special situations 
8.1 RESIDUAL TRANSMISSION
WHO acknowledges that even full implementation of core interventions will 
not be sufficient to completely halt malaria parasite transmission across 
all settings (41). Some residual malaria parasite transmission will occur, 
even with universal access to and usage of ITNs or in areas with high IRS 
coverage. Residual transmission occurs as a result of a combination of 
human and vector behaviours, for example, when people reside in or visit 
forest areas or do not sleep in protected houses, or when local mosquito 
vector species exhibit one or more behaviours that allow them to avoid the 
core interventions, such as biting outside early in the evening before people 
have retired indoors and/or resting outdoors.
There is an urgent need for greatly improved knowledge of the 
bionomics of the different sibling species within malaria vector species 
complexes, and new interventions and strategies in order to effectively 
address residual transmission. While this knowledge is being gained and 
interventions are being developed, national malaria control programmes 
must prioritize the effective implementation of current interventions to 
reduce transmission to the lowest level possible. At the same time, they 
should collaborate with academic or research institutions to generate local 
evidence on the magnitude of the problem of residual transmission of 
malaria, including information on human and vector behaviours, and the 
effectiveness of existing and novel interventions.
Residual transmission is difficult to measure, as is the specific impact 
of supplementary tools on this component of ongoing transmission. 
Standardized methods for quantifying and characterizing this component 
of transmission are required in order to evaluate the effectiveness of 
single or combined interventions in addressing this biological challenge to 
malaria prevention and control and elimination.
8.2 EPIDEMICS AND HUMANITARIAN EMERGENCIES 
In the acute phase of a humanitarian emergency, the first priorities 
for malaria control are prompt and effective diagnosis and treatment. 
Vector control also has the potential to play an important role in reducing 
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transmission. However, the evidence base on the effectiveness of vector 
control interventions deployed in these settings is weak (42).
During the acute phase, decisions on vector control and prevention will 
depend on:
• malaria infection risk;
• behaviour of the human population (e.g. mobility, where they are 
sleeping or being exposed to vector mosquitoes);
• behaviour of the local vector population (e.g. indoor resting, indoor 
biting, early evening or night biting);
• the type of shelter available (e.g. ad-hoc refuse materials, plastic 
sheeting, tents, more permanent housing). 
Effective case management can be supplemented with distribution of ITNs, 
first targeting population groups most susceptible to developing severe 
malaria, but with the ultimate goal of achieving and maintaining universal 
coverage. IRS can also be applied in well-organized settings, such as 
transit camps, but is generally unsuitable where dwellings are scattered 
widely, of a temporary nature (less than three months), or constructed with 
surfaces that are unsuitable for spraying. IRS is best suited for protecting 
larger populations in more compact settings, where shelters are more 
permanent and solid.
Some vector control interventions and personal protection measures 
have been specifically designed for deployment in acute emergency 
situations. Plastic sheeting is sometimes provided in the early stages of 
humanitarian emergencies to enable affected communities to construct 
temporary shelters. In these new settlements, where shelter is very basic, 
use of insecticide-treated plastic sheeting (ITPS) to construct shelters may 
be a practical, acceptable and feasible approach. Laminated polyethylene 
tarpaulins that are impregnated with a pyrethroid during manufacture 
are suitable for constructing such shelters. As with IRS, ITPS is only effective 
against indoor resting mosquitoes, but the degree to which it impacts 
transmission has yet to be confirmed. Moreover, pyrethroid-treated plastic 
sheeting should not be deployed in areas where the local malaria vectors 
are resistant to pyrethroids.
Another intervention with potential for deployment in emergency 
situations is the long-lasting insecticide impregnated blanket or topsheet. 
Blankets or lightweight topsheets are often included in emergency relief 
kits. One advantage of blankets and topsheets is that they can be used 
anywhere people sleep (e.g. indoors, outdoors, any type of shelter). 
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However, as with ITPS, the evidence base regarding the effectiveness of 
this approach is currently limited. Data from community RCTs of long-
lasting pyrethroid-treated wash-resistant blankets and topsheets would 
be required to determine public health value and develop specific policy 
recommendations for deployment as public health interventions.
In the post-acute phase, universal coverage with ITNs or IRS may be 
feasible. Deployment of insecticide-treated plastic sheeting for shelter 
construction may be more practical in situations where ITN use or the 
application of IRS is not possible, although currently there is no WHO policy 
recommendation for this intervention.
8.3 MIGRANT POPULATIONS AND POPULATIONS 
ENGAGED IN HIGH-RISK ACTIVITIES 
As noted above, topical repellents and insecticide-treated clothing 
may be practical interventions for providing personal protection to 
specific populations at risk of malaria due to occupational exposure, 
e.g. military personnel, night-shift workers, forestry workers. However, 
the available evidence does not support the large-scale deployment of 
such interventions for reducing or preventing infection and/or disease 
in humans. Data demonstrating epidemiological impact would be 
required to determine public health value and develop specific policy 
recommendations for deployment as public health interventions to protect 
these populations.
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9. Implementation 
challenges
Vector control plays a vital role in reducing the transmission and burden 
of vector-borne disease, complementing the public health gains achieved 
through disease management. Unfortunately, at present, the potential 
benefits of vector control are far from being fully realized. WHO identifies 
the following reasons for this shortfall (43): 
• The skills to implement vector control programmes remain scarce, 
particularly in the resource-poor countries in most need of effective 
vector-borne disease control. In some cases, this has led to control 
measures being implemented that are unsuitable, poorly targeted or 
deployed at insufficient coverage. In turn, this has led to suboptimal 
resource use and sometimes avoidable insecticide contamination of 
the environment;
• Insecticide application in agriculture and poor management of 
insecticides in public health programmes have contributed to 
resistance in disease vectors; and
• Development programmes, including irrigated agriculture, 
hydroelectric dam construction, road building, forest clearance, 
housing development and industrial expansion, all influence vector-
borne diseases, yet opportunities for intersectoral collaboration and 
for adoption of strategies other than those based on insecticides are 
seldom realized. 
9.1 ACCEPTABILITY, PARTICIPATION AND ETHICAL 
CONSIDERATIONS
Acceptability and end-user suitability of the vector control interventions 
included in the Guidelines were considered when developing the Evidence-
to-Decision Frameworks, as part of the GRADE process.
ITNs are generally acceptable to most communities. In many malaria-
endemic countries, untreated nets were in use for many years prior to the 
introduction of ITNs and, even where there is not a long history of their use, 
they have become familiar tools for preventing mosquito bites. Individuals 
often appreciate the extra privacy afforded by a net, as well as its 
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effectiveness in controlling other nuisance insects. In very hot climates, ITNs 
may be less acceptable, as they are perceived to reduce air flow, making it 
too hot to allow for a comfortable sleep. In areas where mosquito densities 
are low or where malaria transmission is low, individuals and communities 
may perceive less benefit in using nets.
Community acceptance of IRS is critical to the programme’s success, 
particularly as it involves disruption to the household, requiring 
householders to remove certain articles and allow spray teams to enter all 
rooms of the house. Repeated, frequent spraying of houses over extended 
periods can lead to refusal by householders. Reduced acceptance has 
been an impediment to effective IRS implementation in various parts of the 
world (44).
Larviciding for malaria vector control is currently not deployed at the 
scale of LLINs or IRS, and many communities are therefore unfamiliar 
with it. Larviciding is likely to be more acceptable in communities that 
have a good understanding of the lifecycle of mosquitoes and the link 
with the transmission of malaria or other diseases. Community members 
may have concerns about larvicides being applied to drinking water or 
other domestic water sources. A well-designed community sensitization 
programme is required to ensure that communities fully understand the 
intervention and that any concerns about health and safety aspects are 
addressed. 
Community participation in the implementation of vector control 
interventions is often in the form of ‘instruction’ and ‘information’, with 
decisions about the need for interventions being made at international 
and national levels. Taking into account communities’ views on the 
recommended interventions may promote acceptance and adherence 
to the intervention. Increased levels of participation (e.g. consultation, 
inclusion and shared decision-making) should ideally be included in the 
future development of improved and new vector control interventions, from 
inception through to the planning and implementation stages. 
WHO acknowledges that appropriate policy-making often requires 
explicit consideration of ethical matters in addition to scientific evidence. 
However, the ethical issues relevant to vector-borne disease control and 
research have not previously received the analysis necessary to further 
improve public health programmes. Moreover, WHO Member States lack 
specific guidance in this area. The Seventieth World Health Assembly (45) 
requested the Director-General “to continue to develop and disseminate 
normative guidance, policy advice and implementation guidance that 
provides support to Member States to reduce the burden and threat of 
vector-borne diseases, including to strengthen human-resource capacity 
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and capability for effective, locally adapted, sustainable and ethically 
sensitive vector control; to review and provide technical guidance on the 
ethical aspects and issues associated with the implementation of new 
vector control approaches in order to develop mitigating strategies and 
solutions; and to undertake a review of the ethical aspects and related 
issues associated with vector control implementation that include social 
determinants of health, in order to develop mitigating strategies and 
solutions to tackle health inequities.” As a first step towards developing 
appropriate guidelines within the next two years, a scoping meeting was 
convened by WHO to identify the ethical issues associated with vector-
borne diseases (46). Further work has been undertaken to develop 
guidance. Once available, it will be reflected in future editions of the 
Guidelines.
Unique ethical issues associated with vector control that were identified 
at the February 2017 scoping meeting include the ethics of coercive or 
mandated vector control, the deployment of insecticides (and growing 
vector resistance to insecticides), and research on and/or deployment 
of new vector control technologies. Genetically modified mosquitoes are 
one such innovation that presents potential challenges, including how to 
prevent their spread beyond the intended geographical target areas and 
limit potential effects on the local fauna. WHO has established a robust 
evaluation process for new vector control interventions (47) in order 
to ensure that these are fully and properly assessed prior to any WHO 
recommendation for their deployment. 
9.2 EQUITY, GENDER AND HUMAN RIGHTS
The aim of all of the work of WHO is to improve population health and 
decrease health inequities. Sustained improvements to physical, mental 
and social well-being require actions in which careful attention is paid 
to equity, human rights principles, gender and other social determinants 
of health. A heightened focus on equity, human rights, gender and social 
determinants is expressed in the WHO 13th General Programme of Work. 
In pursuit of this outcome, WHO is committed to providing guidance on 
the integration of sustainable approaches that advance health equity, 
promote and protect human rights, are gender-responsive and address 
social determinants into WHO programmes and institutional mechanisms; 
promoting disaggregated data analysis and health inequality monitoring; 
and providing guidance on the integration of sustainable approaches that 
advance health equity, promote and protect human rights, are gender-
responsive and address social determinants into WHO’s support at country 
level (48).
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WHO advocates for universal coverage with recommended vector 
control interventions. As such, malaria vector control is expected to be 
implemented without discrimination on the basis of age, sex, ethnicity, 
religion or other characteristic. In some cases, special effort is required to 
reach populations that are geographically isolated or adopt a nomadic 
lifestyle.
In contrast to the situation observed with HIV and TB, malaria has not 
been associated with systematic discrimination against individuals 
or groups assumed to be at a high risk of infection. However, malaria 
disproportionately affects the most vulnerable populations, including 
the rural poor, pregnant women, children, migrants, refugees, prisoners 
and indigenous populations. For these populations, social inequality and 
political marginalization may impede access to health services, and there 
may be additional barriers created by language, culture, poor sanitation, 
lack of access to health information, lack of informed consent in testing 
and treatment, and inability to pay user fees for medical services. National 
malaria control programmes are increasingly encouraged to identify 
vulnerable groups and situations of inequitable access to services and to 
design approaches, strategies and specific activities to remove human 
rights and gender-related inequities.
9.3 RESOURCE IMPLICATIONS AND PRIORITIZATION
In this 1st edition of the Guidelines, resource implications and the cost-
effectiveness of vector control interventions could largely only be addressed 
through expert opinion. Although it is recognized that such considerations 
should ideally be based on evidence, sufficient clarity on how to collate 
and present data for this area of the Guidelines was not available at the 
time of writing. Expanded evidence-based recommendations on resource 
implications will be developed and incorporated as part of revision to the 
Guidelines. 
At present, the most recent systematic review of the cost and cost-
effectiveness of vector control interventions was published in 2011, drawing 
on studies published between 1990 and 2010 (49). The body of evidence 
collated was based on the use of ITNs/LLINs and IRS in a few sites in 
sub-Saharan Africa. The authors found large variations in the costs of 
intervention delivery, which reflected not only the different contexts but also 
the various types of costing methodologies employed; these studies were 
rarely undertaken alongside clinical and epidemiological evaluations. The 
review reported that, while ITNs/LLINs and IRS were consistently found to 
be cost-effective across studies, evidence to determine their comparative 
cost-effectiveness was insufficient. WHO GMP is working with partners to 
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update the evidence review on the cost and cost-effectiveness evidence of 
the vector control interventions covered in the Guidelines.
Cost-effectiveness analysis – the comparison of the costs and outcomes 
of alternative interventions – can be a helpful tool for measuring the 
magnitude of additional health gained per additional unit of resources 
spent. WHO offers a series of tools to facilitate country-level cost-
effectiveness analysis, notably through the CHOICE project (50). Using the 
cost-effectiveness ratio in combination with cost-effectiveness thresholds, 
as applied in the above-mentioned review, provides some indication of 
the value for money of an intervention. Value for money, however, should 
not be used as a standalone criterion for decision-making, but rather used 
alongside other considerations, including affordability and budget impact 
analysis, among others (51). The development of further guidance to 
inform resource use will be a focus in preparing explicit recommendations 
on resource use as part of the GRADE tables, using work by other WHO 
departments as a guide (52). Given that resource considerations are highly 
context-specific and hence unlikely to be detailed enough to inform the 
prioritization of resources for vector control at country level, further work 
to guide country-level decision-making is also foreseen, but will be outside 
the scope of this global guidance document.
9.4 HUMAN RESOURCES AND ENTOMOLOGICAL 
CAPACITY 
The Global vector control response 2017–2030 (6) notes that effective 
and sustainable vector control is achievable only with sufficient human 
resources, an enabling infrastructure and a functional health system. A 
vector control needs assessment (8) will help to appraise current capacity, 
define what is needed to conduct proposed activities, identify opportunities 
for improved efficiencies in vector control, and guide resource mobilization.
Formulating an inventory of existing human, infrastructural (functioning 
insectary and entomological laboratory for species identification and 
resistance testing, vehicles, spray equipment, etc.), institutional and 
financial resources available, and making an appraisal of existing 
organizational structures for vector control are essential first steps. The 
inventory should cover all resources available at national and subnational 
levels, including districts. A broader appraisal of relevant resources 
available outside of the vector-borne disease programme, including in 
municipal governments, non-health ministries, research institutions and 
implementing partners, should be conducted. An evaluation of career 
structures within national and subnational programmes is also important. 
A comprehensive plan for developing the necessary human, infrastructural 
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and institutional capacity within programmes should be formulated. The 
plan should identify any additional resources and associated costs involved 
in achieving the desired objectives and set out clear terms of reference for 
the different staffing positions required.
Capacity-building priorities for established staff should be defined through 
a comprehensive training needs assessment led by the Ministry of Health 
and aligned with available WHO guidance (53).
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10. Monitoring and 
evaluation of vector 
control  
Monitoring involves routine data collection and reporting to determine 
progress made in the implementation of a programme or strategy. 
Evaluation involves rigorous assessment and attribution of impacts to a 
programme or strategy. The combination of monitoring and evaluation 
facilitates understanding of the cause-and-effect relationship between 
implementation and impact and is used to guide planning and 
implementation, to assess effectiveness, to identify areas for improvement, 
and to account for resources used. 
Monitoring and evaluation of vector control interventions is covered in 
detail in the WHO reference manual on malaria surveillance, monitoring 
and evaluation (23). In addition, a brief synopsis of quality assurance is 
provided below.
10.1 QUALITY ASSURANCE OF VECTOR CONTROL 
INTERVENTIONS
Quality assurance is the implementation of systematic and well-planned 
activities to prevent substandard services or products.
Lower than expected effectiveness may be due to a variety of factors 
related to implementation. These can include incorrect application of the 
intervention, inadequate procurement planning, poor quality of deployed 
products and failure to achieve high coverage. Quality assurance efforts 
should be continuous, systematic and independent. Continuous monitoring 
and supervision are required to ensure that staff are adequately trained 
and follow technical guidelines for pesticide application and personal 
safety. Vector control programmes must include a quality assurance 
programme designed to monitor the effectiveness of the control activities. A 
quality assurance programme should monitor applicator performance and 
control outcomes.
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The WHO Model Quality Assurance System for Procurement Agencies (54) 
details the quality assurance steps and processes involved in procuring 
pharmaceutical products and diagnostics, but the principles are equally 
applicable to vector control products.
For vector control products, the key elements of quality assurance are:
• sourcing only products with a WHO PQ listing for deployment against 
malaria vectors;
• requesting the supplier/manufacturer to provide a Certificate of 
Analysis for each batch of the product actually being supplied;
• pre-shipment inspection and sampling according to WHO guidance 
and/or International Organization for Standardization (ISO) standards, 
performed by an independent sampling agent;
• pre-shipment testing conducted by an independent quality control 
laboratory (WHO prequalified or ISO 17025 or Good Laboratory 
Practice accredited) to determine that the product conforms to 
approved specifications according to the WHO/CIPAC test methods;
• testing on receipt in country (post-shipment quality control testing) 
should only be conducted if specific risks related to transport 
have been identified or specific concerns over potential product 
performance justify this additional expense;
• tender conditions should include provisions for free-of-cost 
replacement of shipments that fail quality control checks and disposal 
of failed lots;
• post-marketing surveillance may be required, depending on the 
product and context, to monitor performance over time in order to 
ensure that products continue to conform to their specifications and/or 
recommended performance as set by WHO. 
For ITNs, this may require testing both physical durability and 
insecticidal efficacy. For IRS products, bioefficacy on sprayed surfaces 
of a different nature (e.g. mud, brick), as applicable, should be 
periodically tested according to WHO procedures when an insecticide is 
first introduced into a country. Subsequent measurement of insecticide 
decay on sprayed surfaces should be done only if necessary, as it 
will incur additional expense. Countries can make post-marketing 
surveillance a priority in cases where there are no country-specific 
data on certain LLIN or IRS products, or where anecdotal data on 
poor performance of certain products may exist. Agreement on the 
need and scope of the proposed activities should be reached by all 
in-country stakeholders, including the national regulatory authority. All 
evaluations should follow WHO guidance. 
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Quality assurance of the field application of vector control interventions 
should form an integral part of the national programme’s strategy and 
should include:
• high-quality training for all staff engaged in field implementation of 
vector control interventions;
• regular supervision, monitoring and follow-up of field operations;
• periodic testing of the quality of IRS operations through WHO cone 
bioassay of sprayed surfaces;
• periodic testing of the insecticide concentration on ITNs using WHO 
cone bioassay and/or chemical analysis.
The WHO cone bioassay (preferably using fully susceptible anophelines 
obtained from insectaries) is currently the only tool available for assessing 
the bioefficacy of ITNs and the quality of the application of IRS insecticides 
to walls and other internal surfaces. Colorimetric assays are under 
development that aim to rapidly quantify the amount of insecticide on 
a sprayed surface in the field without the need for a bioassay on live 
mosquitoes. These colorimetric assays, when available, should enable 
programmes to increase the speed and ease of quality assurance testing 
of IRS applications.
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11. Research agenda to 
support future updates
During the development of this 1st edition of the Guidelines, a number of 
areas were identified that require additional work to enhance the guidance 
provided here. Key areas to be addressed as part of revision to the 
Guidelines: 
• To conduct a systematic review of data on IRS interventions from 
studies other than cluster RCTs. Despite its long tradition and the large 
body of associated operational experience, few RCTs have been 
conducted on IRS. The Guidelines Development Group agreed that the 
strength of the current recommendations on IRS, and their specifics, 
could be enhanced through a systematic review of additional data 
from non-randomized studies. 
• To conduct additional systematic reviews on housing and on two LSM 
interventions, namely habitat modification and manipulation.
• To review current evidence on resource use and draft expanded 
GRADE tables that include this information as an initial step guiding 
the prioritization of interventions. This process should follow examples 
provided in other WHO guidance, such as the interim policy guidance 
on the use of delamanid in the treatment of multidrug-resistant 
tuberculosis (51).
• To develop a chapter to guide the collection of cost data alongside 
research studies for inclusion in the trial design manual recently issued 
by WHO on behalf of the VCAG (54). Collection of cost data early 
on in the process of evaluating new interventions will make a useful 
contribution to building an evidence base on resource use, which can 
be drawn on for subsequent editions of the Guidelines.
• To conduct a systematic review of cost and cost-effectiveness data on 
all vector control interventions in order to complement the evidence 
base upon which recommendations are developed and identify 
knowledge gaps in these areas.
• To identify basic resources associated with the recommendations, 
including health system resources (training, supervision, etc.) to support 
countries in developing their own resource need and budget impact 
assessments.
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• To develop further guidance on the deployment of improved or 
interventions in special situations, for example, with the aim of 
controlling residual transmission and protecting specific populations 
with high occupational exposure to malaria.
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ANNEX 2. OVERVIEW OF WHO GUIDELINE 
DEVELOPMENT PROCESS
STAGE PRIMARY CONTRIBUTOR STEP
Planning
WHO Member State, WHO 
country office or public/private 
entity
• Request guidance on a topic
WHO Technical Unit • Determine if a guidelines document 
is needed; review existing WHO and 
external guidelines
• Obtain approval for guidelines 
development from the director of 
the relevant technical department 
at WHO
• Discuss the process with the 
Guidelines Review Committee (GRC) 
Secretariat and with other WHO 
staff with experience in developing 
guidelines
• Form the WHO Guidelines Steering 
Group
• Identify sufficient resources; 
determine the timeline
WHO Guidelines Steering Group • Draft the scope of the guidelines; 
begin preparing the planning 
proposal
• Identify potential members of the 
Guidelines Development Group and 
its Chair
• Obtain declarations of interest and 
manage any conflicts of interest 
among potential Guidelines 
Development Group members
WHO Guidelines Steering Group 
and Guidelines Development 
Group
• Formulate key questions in PICO 
(Population, participants or patients; 
intervention or indicator; comparator 
or control; outcome) format; 
prioritize outcomes
WHO Guidelines Steering Group • Finalize the planning proposal and 
submit it to the GRC for review
Guidelines Review Committee • Review and approve the planning 
proposal
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Development
Systematic review team • Perform systematic reviews of the 
evidence for each key question
• Evaluate the certainty of the 
evidence for each important 
outcome, using Grading of 
Recommendations Assessment, 
Development and Evaluation 
(GRADE) as appropriate
WHO Guidelines Steering Group • Convene a meeting of the Guidelines 
Development Group
Guidelines Development Group • Formulate recommendations using 
the GRADE framework
WHO Guidelines Steering Group • Draft the guidelines document
External Review Group • Conduct external peer review
Publishing 
and updating
WHO Guidelines Steering Group 
and editors
• Finalize the guidelines document; 
perform copy-editing and technical 
editing; submit the final guidelines to 
the GRC for review and approval
Guidelines Review Committee • Review and approve the final 
guidelines
WHO Guidelines Steering Group 
and editors
• Finalize the layout; proofread
• Publish (online and in print as 
appropriate)
WHO Technical Unit and 
Programme Manager
• Disseminate, adapt, implement, 
evaluate
WHO Technical Unit • Update
GRADE: Grading of Recommendations Assessment, Development and Evaluation; 
GRC: Guidelines Review Committee; PICO: Population, participants or patients; 
intervention or indicator; comparator or control; outcome.
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ANNEX 3. CRITERIA USED IN THE EVIDENCE-TO-
DECISION FRAMEWORK
CRITERION EXPLANATION
Is the problem a priority? Are the consequences of the problem serious (i.e. severe or 
important in terms of the potential benefits or savings)? Is 
the problem urgent? Is it a recognized priority (e.g. based 
on a national health plan)? Are a large number of people 
affected by the problem?
How substantial are the desirable 
anticipated effects?
How substantial (large) are the desirable anticipated effects 
(including health and other benefits) of the option (taking 
into account the severity or importance of the desirable 
consequences and the number of people affected)?
How substantial are the 
undesirable anticipated effects?
How substantial (large) are the undesirable anticipated 
effects (including harms to health and other harms) of the 
option (taking into account the severity or importance of the 
adverse effects and the number of people affected)?
What is the overall certainty of the 
evidence of effects?
The less certain the evidence for critical outcomes, the less 
likely it is that an option should be recommended.
Is there important uncertainty 
about or variability in how much 
people value the main outcomes?
How much do those affected by the proposed intervention 
value the outcomes in relation to the other outcomes? Is 
there evidence of variability in those values that is large 
enough to lead to different decisions?
Does the balance between 
desirable and undesirable effects 
favour the intervention or the 
comparison?
The larger the differences between the desirable and 
undesirable consequences, the more likely it is that a strong 
recommendation is warranted. The smaller the net benefit 
and the lower certainty for that benefit, the more likely it is 
that a weak recommendation is warranted.
How large are the resource 
requirements (costs)?
The higher the costs of an intervention (the more resources 
consumed), the less likely it is that a strong recommendation 
is warranted.
What is the certainty of the 
evidence of resource requirements 
(costs)?
The higher the certainty of the evidence of resource 
requirements, the more confidence there is in making a 
recommendation for or against the intervention.
Does the cost-effectiveness 
of the intervention favour the 
intervention or the comparison?
The more cost-effective an intervention, the more likely it is 
that it will be recommended over the comparison.
What would be the impact on 
health equity?
Would the option reduce or increase health inequities? 
Policies or programmes that reduce inequities are more 
likely to be a priority than ones that do not (or ones that 
increase inequities).
Is the intervention acceptable to 
key stakeholders?
Are key stakeholders likely to find the option acceptable 
(given the relative importance they attach to the desirable 
and undesirable consequences of the option; the timing of 
the benefits, harms and costs; and their moral values)? The 
less acceptable an option is to key stakeholders, the less 
likely it is that it will be recommended.
Is the intervention feasible to 
implement?
The less feasible (capable of being accomplished or 
brought about) an option is, the less likely it is that it will be 
recommended (i.e. the more barriers there are that would 
be difficult to overcome).
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ANNEX 4. GRADE TABLES ASSESSING THE CERTAINTY 
OF EVIDENCE
The Annex gives the results of Grading and Recommendations, Assessment, 
Development and Evaluation (GRADE) based on responses to questions 
of importance to populations at risk of malaria (population, participants 
or patients; intervention or indicator: comparator or control; outcome: 
PICO) and the results recommendations. The GRADE system is a uniform, 
widely adopted approach based on explicit methods for grading the 
certainty of evidence in support of recommendations in health care. 
The method ensures a transparent link between the evidence and the 
recommendations. 
The PICO questions addressed were as follows:
Core interventions
A4.1 ITNs alone What is the current effect of ITNs (compared to no nets, and to untreated nets)?
A4.2 IRS
a. What is the effect of IRS alone?
b. What is the effect of IRS compared to ITNs?
A4.3 Combining IRS with ITNs
Is the combined deployment of IRS and ITNs more effective in 
reducing malaria transmission than the deployment of ITNs 
alone? 
Supplementary interventions
A4.4 Larviciding Does larviciding (with insecticide, insect growth regulators, microbial agents, or oils) control malaria?
A4.5 Larvivorous fish In malaria transmission settings, are larvivorous fish effective for malaria control?
Other interventions
A4.6 Space spraying
In malaria transmission settings, is space spraying effective for 
malaria control alone or in combination with core interventions, 
compared to any of the core interventions?
A4.7 Repellents
a. Do topical repellents reduce malaria?
b. Does insecticide-treated clothing reduce malaria?
c. Do spatial/airborne repellents reduce malaria?
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A4.1 What is the current effect of ITNs (compared to no nets, and to 
untreated nets)?
Recommendation
Insecticide-treated nets are recommended as a malaria prevention and control 
intervention.
Strength of recommendation
For Intervention No Recommendation Against Intervention
Strong Conditional Conditional Strong
STRONG
Overall certainty of evidence for all critical outcomes
High Moderate Low Very Low
HIGH
Balance of desirable and undesirable effects
Desirable Undesirable
• ITNs significantly reduce all-cause child 
mortality, malaria mortality, P. falciparum 
incidence and prevalence, and incidence 
of severe disease compared to no nets.
• No undesirable effects identified in 
systematic review.
• May play an as yet undetermined role 
in insecticide resistance development in 
Anopheles vectors.
• Some users complain that they are too hot 
to sleep under.
• Brand new nets recently removed from 
packaging may cause slight, transitory 
irritation to skin, eyes, nose, etc. 
Rationale for the recommendation
ITNs generate significant desirable effects in terms of reducing deaths, clinical disease and 
infections compared to no nets (HIGH certainty evidence) and to untreated nets (HIGH 
certainty evidence). Undesirable effects of ITNs are considered to be trivial.
Remarks
The evidence review followed the original 2003 analysis which included insecticide-treated 
curtains and ITNs together, and includes two studies solely evaluating insecticide-treated 
curtains and one study evaluating both ITNs and insecticide-treated curtains. There was 
no obvious heterogeneity (that would lead to a subgroup analysis to examine if the effects 
were different) and the results from studies evaluating insecticide-treated curtains were 
consistent with the results of those evaluating ITNs. The Guidelines Development Group 
drew on the analysis to make recommendations related to ITNs only.
Implementation considerations
• Universal coverage should be achieved and maintained in endemic settings
Monitoring and evaluation
• Improved post-distribution monitoring of nets is needed: durability, usage, coverage 
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Research priorities
• Determine the effectiveness of next-generation nets and insecticides in areas where 
resistance to pyrethroids is high
• Generate evidence for assessing the impact of insecticide resistance on key outcomes 
(malaria mortality, clinical disease and prevalence of infection)
• Determine the comparative effectiveness of different net types
• Determine the effectiveness of nets in situations of residual/outdoor transmission
• Determine the role of ITN deployment in transmission ‘hotspots’ and elimination settings
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A4.2a. What is the effect of indoor residual spraying alone?
Recommendation
IRS is recommended for populations at risk of malaria in most epidemiological and ecological 
scenarios. IRS is one of the core interventions currently recommended for malaria vector control 
and should continue to be so.
Rationale for the recommendation
The certainty of the evidence subjected to systematic review is graded LOW. The Guidelines 
Development Group considers that despite the LOW certainty of the evidence included in the 
systematic review, a strong recommendation for the intervention is warranted based on the 
fact that there is a considerable body of evidence stretching back several decades pertaining to 
implementation trials and programmatic data. The Guidelines Development Group considers that 
this body of evidence, when viewed as a whole, provides strong evidence of the effectiveness of 
IRS as a malaria prevention and control intervention.
Strength of recommendation
For Intervention No Recommendation Against Intervention
Strong Conditional Conditional Strong
STRONG
Overall certainty of evidence for all critical outcomes
High Moderate Low Very Low
LOW
Balance of desirable and undesirable effects
Desirable Undesirable
• IRS significantly reduces all-cause child 
mortality, malaria mortality, P. falciparum 
incidence and prevalence, and incidence of 
severe disease compared to no IRS.
• No undesirable effects identified in 
systematic review.
• May play an as yet undetermined role 
in insecticide resistance development in 
Anopheles vectors.
• Requires householders to grant permission 
for spray team to enter house.
• Requires householders to remove personal 
items from houses prior to spraying (e.g. 
foodstuffs).
• Some insecticide formulations leave unsightly 
residue on sprayed surfaces.
Remarks
Implementation considerations
• Decisions on selection of insecticide to be used will depend on the resistance profile of the local 
vector population.
• High (universal) coverage should be maintained in endemic settings. 
• The primary vector should be endophilic.
• Implementation of the intervention should take place prior to the onset of the peak transmission 
season.
Monitoring and evaluation
• Residual activity of the insecticide(s)
Research priorities
• Impact of IRS in urbanized areas with changing housing designs
• Impact of IRS on insecticide-resistant populations
• Generate high-quality evidence on the impact of insecticide rotations as an insecticide 
resistance management tool
• Impact of IRS in different mosquito behaviour/settings (outdoor transmission)
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A4.2b. What is the effect of IRS compared to ITNs?
Recommendation
IRS and ITNs are both recommended as malaria prevention and control interventions in most 
epidemiological and ecological scenarios. 
Rationale for the recommendation
The certainty of the evidence subjected to systematic review is graded LOW. The Guidelines 
Development Group considers that despite the LOW certainty of the evidence included in the 
systematic review, a strong recommendation for the intervention is warranted based on the 
fact that there is a considerable body of evidence stretching back several decades pertaining to 
implementation trials and programmatic data. The Guidelines Development Group considers this 
body of evidence, when viewed as a whole, provides strong evidence of the effectiveness of IRS 
as a malaria prevention and control intervention. Insecticide-treated nets are considered to be an 
equally effective alternative intervention.
Strength of recommendation
For Intervention No Recommendation Against Intervention
Strong Conditional Conditional Strong
STRONG
Overall certainty of evidence for all critical outcomes
High Moderate Low Very Low
LOW
Balance of desirable and undesirable effects
Desirable Undesirable
• IRS may decrease the incidence of malaria 
compared to ITNs. There may be little or no 
difference in parasite prevalence between 
IRS and ITNs. 
• No undesirable effects identified in 
systematic review.
• May play an as yet undetermined role 
in insecticide resistance development in 
Anopheles vectors.
• Requires householders to grant permission 
for spray team to enter house.
• Requires householders to remove personal 
items from houses prior to spraying (e.g. 
foodstuffs).
• Some insecticide formulations leave unsightly 
residue on sprayed surfaces.
Remarks
The evidence review followed the original 2003 analysis, which included insecticide-treated 
curtains and ITNs together, and includes two studies solely evaluating insecticide-treated curtains 
and one study evaluating both ITNs and insecticide-treated curtains. There was no obvious 
heterogeneity (that would lead to a subgroup analysis to examine if the effects were different) 
and the results from studies evaluating insecticide-treated curtains were consistent with the 
results of those evaluating ITNs. The Guidelines Development Group drew on the analysis to make 
recommendations related to ITNs only.
Implementation considerations
• Decisions on selection of insecticide to be used for IRS will depend on the resistance profile of 
the local vector population
• High (universal) coverage should be maintained 
• The primary vector should be endophilic
• Implementation of the intervention should be timely
100
Monitoring and evaluation
• Residual activity of the insecticide(s)
Research priorities
• Impact of IRS in urbanized areas with changing housing designs
• Impact of IRS on insecticide-resistant populations
• Generate high-quality evidence on the impact of insecticide rotations as an insecticide 
resistance management tool
• Impact of IRS in different mosquito behaviour/settings (outdoor transmission)
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A4.3. Is the combined deployment of IRS and ITNs more effective in 
reducing malaria transmission than the deployment of ITNs alone?
Recommendations
Malaria control and elimination programmes should prioritize the delivery of either ITNs or IRS 
at high coverage and to a high standard, rather than introducing the second intervention as a 
means to compensate for deficiencies in the implementation of the first.
Addition of IRS with a non-pyrethroid insecticide to high ITN coverage is recommended where 
pyrethroid resistance is potentially compromising the effectiveness of ITNs. In areas where no 
operational implication of pyrethroid resistance has been confirmed, IRS in addition to high ITN 
coverage is not recommended.
Pyrethroid IRS is not recommended in combination with ITNs.
Strength of recommendation
For Intervention No Recommendation Against Intervention
Strong Conditional Conditional Strong
CONDITIONAL
Overall certainty of evidence for all critical outcomes
High Moderate Low Very Low
MODERATE
Balance of desirable and undesirable effects
Desirable Undesirable
• None identified in systematic review.
• In areas of confirmed pyrethroid resistance, 
IRS with a non-pyrethroid insecticide may 
increase effectiveness against malaria.
• None identified in systematic review.
• The cost of combining two interventions 
will significantly increase commodity and 
operational costs.
Rationale for the recommendation
The systematic review did not provide evidence of a benefit of adding IRS in situations where ITNs 
are already being used. MODERATE certainty of evidence. Non-pyrethroid IRS in addition to ITNs 
(“combination”) is potentially useful as an insecticide resistance management approach in areas 
of pyrethroid resistance. Evidence for any additional benefit in such situations is required.
Remarks
Implementation considerations 
• The degree of pyrethroid resistance and its impact on the effectiveness of ITNs
• Status of vector resistance to the proposed IRS active ingredient
• In resource-constrained situations, it is unlikely to be financially feasible to deploy both core 
interventions together.
Monitoring and evaluation 
• Entomological surveillance, including population densities, EIRs and behaviour, is required.
• Insecticide resistance status and investigations of cross-resistance
• Quality control of the IRS and ITNs
• Coverage (access and use) of ITNs
• Coverage of IRS
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Research priorities
• The evidence base for combining non-pyrethroid IRS with ITNs in the context of insecticide 
resistance management needs to be expanded.
• The acceptability of combined interventions by householders and communities needs to be 
determined.
• The evidence for an impact of IRS + ITNs vs IRS only needs to be explored and synthesized.
• Correlating entomological outcomes (from experimental hut trials and cone bioassays) with 
epidemiological outcomes is required.
• New tools for monitoring the quality of IRS and ITN interventions are needed.
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A4.4. Does larviciding (with insecticide, insect growth regulators, 
microbial agents, or oils) control malaria?
Recommendation
Larviciding could be recommended for malaria control as a supplementary intervention in specific 
settings where the application is both feasible and cost-effective. These settings are generally 
areas where aquatic habitats are few, fixed and findable. Larviciding is likely to be less feasible in 
areas where the aquatic habitats are abundant, scattered and variable. Determination of whether 
or not specific habitats are suitable for larviciding should be based on expert technical opinion 
and knowledge.
Strength of recommendation
For Intervention No Recommendation Against Intervention
Strong Conditional Conditional Strong
CONDITIONAL
Overall certainty of evidence for all critical outcomes
High Moderate Low Very Low
LOW
Balance of desirable and undesirable effects
Desirable Undesirable
• None identified in systematic review • None identified in systematic review
• May affect non-target fauna
• Communities may not accept its application 
to sources of drinking water or water used 
for other domestic purposes.
Rationale for the recommendation
Larviciding is deployed for malaria control in several countries, including Somalia and Sudan; 
however, certainty of the evidence of epidemiological effects is low or very low.
Remarks
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A4.5. In malaria transmission settings, are larvivorous fish effective for 
malaria control?
Recommendation
No recommendation can be made because evidence on the effectiveness or harms of larvivorous 
fish was not identified.
Strength of recommendation
For Intervention No Recommendation Against Intervention
Strong Conditional Conditional Strong
NO RECOMMENDATION
Overall certainty of evidence for all critical outcomes
High Moderate Low Very Low
NO STUDIES INCLUDED
Balance of desirable and undesirable effects
Desirable Undesirable
• None identified in the systematic review
• Fish can serve as an additional source of 
nutrition.
• None identified in the systematic review.
Rationale for the recommendation
There is insufficient evidence to support an effect of larvivorous fish on malaria transmission or 
disease outcomes. The Guidelines Development Group recognizes that there are specific settings 
in which the intervention is currently implemented, and in these specific settings programme 
staff consider it to be effective. In some of the settings where larvivorous fish are being deployed, 
programmatic evidence exists; however, this was not determined appropriate for inclusion in the 
systematic review due to unsuitable study design or other concerns. The Guidelines Development 
Group acknowledges that there may be data at country/programme level that it is not aware of.
Remarks
Implementation considerations
• There is evidence that this intervention would require mosquito aquatic habitats to be large, 
permanent and few 
• There is a need for local capacity for breeding fish, maintaining fish and monitoring aquatic 
habitats
Monitoring and evaluation
• There is a need to summarize the characteristics of settings in which this intervention might be 
applicable
Research priorities
• Well-designed epidemiological studies (not larval density sampling) should be conducted in 
areas where programmes include larvivorous fish in order to generate an evidence base
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A4.6. In malaria transmission settings, is space spraying effective 
for malaria control alone or in combination with core interventions, 
compared to any of the core interventions?
Recommendation
In the absence of high-quality evidence on the effectiveness of space spraying, and considering 
other factors including cost and anticipated cost-effectiveness, core malaria vector control 
interventions (ITNs and IRS) should be prioritized over space spraying in the majority of settings. 
Strength of recommendation
For Intervention No Recommendation Against Intervention
Strong Conditional Conditional Strong
CONDITIONAL
Overall certainty of evidence for all critical outcomes
High Moderate Low Very Low
VERY LOW
Balance of desirable and undesirable effects
Desirable Undesirable
• No desirable effects identified by systematic 
review.
• No undesirable effects identified by 
systematic review.
Rationale for the recommendation
Only observational studies were available, graded as VERY LOW certainty evidence. Anticipated 
desirable effects of space spraying are likely to be small, as insecticide formulations used are 
short-lived. Anopheles mosquitoes are generally considered to be less susceptible to space 
spraying than Culex or Aedes. Space spraying is frequently applied when cases are at their peak, 
which is followed by a decline in cases, whether or not control measures are applied. The high 
costs and limited anticipated cost-effectiveness of this intervention dissuade its deployment.
Remarks
Implementation considerations
• Specialist technical equipment required
Research priorities
• Demonstrate evidence of impact, particularly in emergency situations, through design of high-
quality trials
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A4.7a Do topical repellents reduce malaria?
Recommendation
Deployment of topical repellents for malaria prevention is not currently recommended as a public 
health intervention. Topical repellents may be beneficial as a tool to provide personal protection 
against malaria..
Strength of recommendation
For Intervention No Recommendation Against Intervention
Strong Conditional Conditional Strong
CONDITIONAL
Overall certainty of evidence for all critical outcomes
High Moderate Low Very Low
LOW
Balance of desirable and undesirable effects
Desirable Undesirable
• No desirable effects identified in systematic 
review.
Rationale for the recommendation
The systematic review assessed that the evidence of a benefit from the deployment of topical 
repellents as a malaria prevention tool in a public health setting is of LOW certainty. Based on 
expert opinion and in line with current WHO recommendations, topical repellents may still be 
useful in providing personal protection against malaria.
Remarks
Research priorities
• Investigations of the potential public health value of topical repellents in specific settings and 
target populations
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A4.7b Does insecticide treated clothing reduce malaria?
Recommendation
Deployment of insecticide-treated clothing for malaria prevention is not currently recommended 
as a public health intervention. Such clothing may be beneficial as a tool to provide personal 
protection against malaria in specific population groups (refugees, military).
Strength of recommendation
For Intervention No Recommendation Against Intervention
Strong Conditional Conditional Strong
CONDITIONAL
Overall certainty of evidence for all critical outcomes
High Moderate Low Very Low
LOW
Balance of desirable and undesirable effects
Desirable Undesirable
• Evidence of an effect on clinical P. falciparum 
and P. vivax malaria in specific population 
groups.
• No undesirable effects identified in 
systematic review.
Rationale for the recommendation
The systematic review identified some LOW certainty evidence of an effect on clinical P. falciparum 
and P. vivax malaria in specific population groups. No evidence was available on epidemiological 
effects in the general at-risk population. 
Remarks
Research priorities
• Investigations of potential epidemiological impact on malaria in the general population
• Identification of approaches to increase compliance
• Development of formulations that improve the durability of insecticidal efficacy
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A4.7c Do spatial/airborne repellents reduce malaria?
Recommendation
No recommendation on the deployment of spatial/airborne repellents in the prevention and 
control of malaria can be made until more studies assessing malaria epidemiological outcomes 
have been conducted and published.
Strength of recommendation
For Intervention No Recommendation Against Intervention
Strong Conditional Conditional Strong
NO RECOMMENDATION
Overall certainty of evidence for all critical outcomes
High Moderate Low Very Low
VERY LOW
Balance of Desirable and Undesirable Effects
Desirable Undesirable
• None identified in systematic review. • None identified in systematic review.
Rationale for the recommendation
The systematic review identified only two studies with high risk of bias, imprecision and 
inconsistency, resulting in VERY LOW certainty of evidence of an effect. It is therefore unknown 
whether spatial/airborne repellents protect against malaria parasitaemia.
Remarks
Research priorities
• Investigation of the potential for a 'push–pull' effect of spatial/airborne repellents, whereby 
vector mosquitoes may simply move from a treated area to a neighbouring untreated area 
• Good quality, well-designed trials generating epidemiological evidence on the effects of 
spatial/airborne repellents as a malaria prevention and control tool
• Development of better insecticide formulations that provide a longer lasting effect
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